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Abstract 
Hydralazine is a vasodilator that has been in clinical use for nearly six decades. Despite this, 
the mechanism of its action in human blood vessels is uncertain. Understanding how 
hydralazine works may have importance for the better treatment of heart failure and other 
cardiovascular diseases. In the first Vasodilator Heart Failure trial, hydralazine was shown, in 
combination with oral nitrates, to reduce mortality in patients with heart failure, treated at a 
time when the benefits of ACE inhibitors, beta-blockers and mineralocorticoid receptor 
antagonists were not known. As the combination of hydralazine and isosorbide dinitrate was 
subsequently shown to be less effective than an ACE inhibitor in the second Vasodilator Heart 
Failure trial, it was little used. Recently, however, the same combination was shown to reduce 
mortality and morbidity in the African-American Heart Failure Trial. Crucially, in this trial, 
the patients were already treated with the best currently available drug therapy. Though the 
patients studied were self-designated African-Americans, it is widely believed that the 
incremental benefits of the combination of hydralazine and isosorbide dinitrate are as likely to 
be obtained in other patients. 
 
While the vasodilator action of nitrates is well understood, a better understanding of the action 
of hydralazine (and its interaction with nitrates) could lead to the development of more 
effective and/or better-tolerated drugs. Nitrate therapy is limited by the development of 
pharmacological tolerance, possibly secondary to the increased production of reactive oxygen 
species. Hydralazine co-treatment has been shown to prolong the vasodilator effect of nitrates 
in animal models and clinical studies, although the mechanism of this protection in humans is 
uncertain. There are many postulated mechanisms of the vasodilator action of hydralazine, 
based upon studies carried out - mostly in animals - or animal tissues. Hydralazine reduces 
contractile responses to a number of vasoconstrictors, and this effect appears greater in arteries 
than in veins. The most (though not entirely) consistent findings are those suggesting that 
hydralazine leads to the activation of guanylate cyclase. This action to increase intracellular 
cGMP, could explain the favourable clinical benefits of its combination with oral nitrates.  
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Hydralazine may affect a number of other vascular enzymes. These include key regulators of 
vascular superoxide production such as NAD(P)H oxidases. These systems are regulated in 
vivo and ex vivo by angiotensin-II and aldosterone, and are believed to be pivotal in the 
development of endothelial dysfunction, a key pathophysiological abnormality in heart failure. 
Renin-angiotensin system activation and oxidative stress are important (and inter-related) 
pathophysiological processes in heart failure and other cardiovascular problems. There is 
experimental evidence that hydralazine may inhibit these vascular and mitochondrial oxidases, 
and may also act as a radical scavenger, thus helping restore the balance between NO and 
superoxide in endothelial dysfunction.  Inhibition of superoxide production may also help 
prevent nitrate tolerance: this may be critical in permitting therapeutic synergy between 
hydralazine and nitrates. However, the evidence emanating from different animal species is 
contradictory. Surprisingly, the antioxidant effect of hydralazine has never been directly 
characterised in human blood vessels. 
 
In this thesis I investigated the action of hydralazine in human blood vessels. To make this 
project clinically relevant, I characterised the actions of hydralazine in arteries and veins of 
various calibre (saphenous vein and internal mammary artery taken at the time of coronary 
artery bypass surgery and subcutaneous resistance arteries dissected from gluteal biopsies), 
from patients with low ejection fraction heart failure secondary to coronary artery disease. I 
also investigated the purported ability of hydralazine to reduce vascular superoxide 
production. 40 patients undergoing elective coronary artery bypass surgery were recruited for 
large vessel studies and 20 patients underwent gluteal biopsy, which yielded subcutaneous 
resistance arteries. Vascular reactivity was assessed using organ bath techniques and wire 
myography with the construction of cumulative concentration response curves. Production of 
vascular superoxide was measured using lucigenin chemiluminescence. 
 
 
 
 
 
 
 
 
	   4	  
Summary of results: 
 
1. There was no direct vasodilator effect of hydralazine at therapeutic concentrations (<1 
µmol/L). This suggests that the favourable benefits of hydralazine are not simply 
dependent on direct vasodilatation.  
 
2. There was a modest – but not statistically significant – interaction between hydralazine 
and endothelium-dependent vasodilatation using carbachol. This is consistent with a trend 
of potential biological relevance. There was a similarly modest interaction with organic 
nitrates. These data are consistent with theories that the therapeutic benefits of hydralazine 
may be partly explained by improved endothelium-dependent vasodilatation and that the 
interaction with organic nitrates in vivo is not simply dependent on augmented 
vasodilatation.  
 
3. Hydralazine reduced basal superoxide production in both internal mammary artery [1.09 ± 
0.14 nmol/mg/min vs. 0.77 ± 0.16 nmol/mg/min (P=0.026) controls and pre-treated vessels 
respectively] and saphenous veins [0.77 ± 0.08 nmol/mg/min vs. 0.68 ± 0.08 nmol/mg/min 
(P=0.018) controls and pre-treated vessels respectively]. A dose-response in superoxide 
production in saphenous vein (which were more readily available for experimentation) was 
also evident.   
 
4. Hydralazine significantly inhibited angiotensin-II mediated superoxide production in 
internal mammary arteries [1.68 ± 0.434 nmol/mg/min vs. 0.843 ± 0.144 nmol/mg/min 
(P=0.032) controls and pre-treated vessels respectively]. Angiotensin II plays a key role in 
the pathophysiology of heart failure, with pleotropic effects including increased vascular 
superoxide production through stimulation of NAD(P)H oxidase. Attenuation of 
angiotensin-II stimulated superoxide production by hydralazine could mechanistically be 
through interaction with the NAD(P)H oxidase enzyme group; supporting the best 
available animal data suggesting that hydralazine prevents nitrate tolerance through 
modulation of this enzyme group.  
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Appropriate recognition must be had to the limitations innate in this work and recognise that 
all protocols were ex vivo and, as such, none could accurately reflect the complex phenotype 
recognised in chronic heart failure. The relatively small sample sizes in the study protocols 
must also be given recognition; however, my group - and others - have published, 
scientifically meaningful results utilising similar sample sizes. Future developments ought to 
include larger scale bench and in vivo studies of hydralazine and organic nitrate interaction 
with particular emphasis on assessing endothelium-dependent vasodilatation. In my studies 
hydralazine functionally reduced vascular superoxide production; future studies will evaluate 
this mechanistically with particular emphasis on the NAD(P)H oxidase system.  
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1.1 Heart Failure 
 
Heart failure is a progressive, debilitating disorder affecting approximately 2-5% of the adult 
population of the developed World and is associated with considerable mortality and 
morbidity(1).  Heart failure impacts on the quality and duration of life and places considerable 
economic burden on our healthcare systems(2). Whilst age-adjusted incidence appears to be 
stable, prevalence is thought to be increasing, principally as a consequence of an ageing 
population and improved survival from coronary artery disease.  Our greater appreciation of 
the pathophysiology and natural history of heart failure has allowed development of targeted 
therapy to achieve symptom control, reduce hospital admissions and prolong life. On the basis 
of large, randomised controlled trials, drugs are the established mainstay of treatment. The 
resulting benefits of these developments appear to have been translated to the greater 
unselected population with observational studies indicating improvements in outcome, which 
temporally correlate with the emergence of evidenced-based therapy(3).  
 
1.1.2 Definition of heart failure 
 
Heart failure is a term used to describe a commonly observed clinical syndrome resulting from 
impaired cardiac function. A systemic disease, never occurring in isolation, heart failure is 
often the terminal manifestation of a legion of cardiovascular and non-cardiovascular 
conditions, characterised by maladaptive physiological responses including neurohormonal 
activation, low grade inflammation and molecular adaptations resulting in progressive 
impaired cardiac performance(4).  Contemporary clinical practice guidelines require the 
presence of symptoms and signs of the heart failure syndrome along with objective evidence 
of cardiac dysfunction(5).  Many of these symptoms and signs are relatively non-specific and 
do not arise as a direct consequence of the underlying mechanical cardiac disruption, but 
through secondary dysfunction in other organ systems. Our understanding of the 
pathophysiology of heart failure has expanded from a simple haemodynamic model to that of a 
complex multi-system syndrome(6).  
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1.1.3 Epidemiology of heart failure 
 
Despite the considerable health-economic burden of heart failure, its epidemiology is still 
poorly defined, especially in primary care(1). In general terms, contemporary analyses can be 
divided into those examining the prevalence and incidence of symptomatic heart failure (some 
of whom may have preserved left ventricular systolic function) and those investigating the 
prevalence of left ventricular systolic dysfunction (LVSD) (of which a significant proportion 
of patients will be asymptomatic).  These contrasting approaches explain the epidemiological 
inconsistencies in observational studies. Ideally, estimates of heart failure epidemiology would 
emanate from surveys of random samples of the general population, using validated 
questionnaires and targeted physical examinations, in conjunction with objective measures of 
LVSD such as imaging, possibly supported by validated biomarkers i.e., B-type natriuretic 
peptides(7). 
 
1.1.4 Prevalence of heart failure 
 
Epidemiological studies utilising a range of designs suggest that the prevalence of heart failure 
occurs in around 2-5% of the population in the developed world, increasing considerably with 
age(1).  Prevalence varies widely from 0.4% to 19% in older age groups based on general 
practice studies in the UK(8, 9). This trend is also observed in landmark population-based 
cohort studies such as the Framingham study where prevalence of heart failure in 50-59 year 
olds was 0.8% in contrast to 9.1% in those above 80 years of age and the European Rotterdam 
study where overall prevalence was 3.7% increasing to 13.0% in those over 85 years(10, 11).  
In Scotland, a national primary care survey estimated the prevalence of heart failure to be 7.1 
per 1000 population, increasing with age to 90.1 per 1000 patients in the very elderly (>85 
year of age)(12).  All the foregoing data is supported by contemporary studies across the 
developed world(13-15).  
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1.1.5 Incidence of heart failure 
 
The incidence of heart failure is more difficult to define, but there are considerable data 
available, particularly from large population-based studies. In the Framingham Heart study, at 
34 years follow-up, incidence was approximately 2/1000 person-years in subjects aged 45-54, 
increasing to 40/1000 in men aged 85-94(10). Similar patterns were reported in the Olmsted 
County Study and UK and Finnish population studies(16-18).  A prospective cohort study 
undertaken in the UK identified new cases from a population of 151 000 in London, through 
the surveillance of hospital admissions and referrals to a rapid-access specialist heart failure 
clinic(19). Diagnosis of heart failure was confirmed by a panel of cardiologists and supported 
by echocardiography. Incidence was 1.3/1000 overall for those over the age of 25 years. 
Incidence increased with age and was higher in men than women. Whilst prevalence is 
thought to be increasing, age-adjusted incidence is stable. The Resource Utilization Among 
Congestive Heart Failure (REACH) study retrospectively examined incidence in hospitals in 
Michigan USA over a 10-year period; the incidence of heart failure in 1999 was 3.7/1000 
person-years in men and 4.2/100 person-years in women of all ages with no changes between 
1989 and 1999(20).  Overall, in Europe and North America, the lifetime risk of developing 
heart failure is approximately one in five for a 40-year old(21, 22).  
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1.1.6 Prognosis of heart failure 
 
Heart failure prognosis remains poor, despite considerable therapeutic advances. Population 
data suggest that heart failure mortality is comparable to that of cancer. In the Framingham 
Heart study, 5-year mortality was as high as 75% in men(23). Mortality rates in women were 
slightly more favourable at 46% and 62% respectively. Similarly in a UK study, 1- and 5-year 
mortality following an index admission was 43% and 73% respectively; risk proportionate to 
increasing ages(24). In the Rotterdam study, survival rates for prevalent heart failure were 
more favourable, with 1- and 5-year survival rates of 89% and 59% respectively(25). This still 
represents a threefold increase in the age and gender matched population risk. In the Olmsted 
County Study, age-adjusted 5-year survival improved from 43% in 1979-84 to 52% in 1990-
2000(26). This leads to the conclusion that prognosis does appear to be improving. Recent 
Scottish data suggest a sustained improvement in age-adjusted survival following first heart 
failure admission, which temporally correlates to emergence and uptake of effective evidence 
based therapies (figures 1-1, 1-2)(3).  
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Figure 1.1: Adjusted 30-day (A), 1-year (B) and 5-year (C) mortality according to  
sex and year of admission (from Jhund et al (3)).  
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Figure 1-2: Age-adjusted trends in prescribing rates for ACE inhibitors, beta-blockers, 
and spironolactone in patients with HF in primary care (from Jhund et al)(3).  
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1.1.6 Aetiology and pathophysiology of heart failure 
 
Heart failure never occurs in isolation.  
 
Any structural, mechanical or electrical abnormality of the heart can lead to dysfunction and a 
cascade of events leading to heart failure syndrome. As such, heart failure is a classic 
illustration of the cardiovascular disease continuum, whereby multiple, overlapping 
mechanisms are involved in disease progression(4). LVSD develops gradually, often 
beginning with an index event - or injury (such as myocardial infarction) - leading to 
progressive loss of functioning myocytes and consequent maladaptive ventricular remodelling. 
This remodelling process may persist despite further discrete injury and is accelerated by 
concomitant risk factors such as hypertension, diabetes mellitus, cigarette smoking and 
elevated cholesterol levels.  
 
In the developed world, coronary artery disease, either alone or in combination with 
hypertension appears to be the dominant cause of heart failure(1, 27). In a patient with 
multiple risk factors the definitive aetiology may not be immediately apparent.  The use of 
adjunctive diagnostic tools including nuclear perfusion imaging or cardiac catheterisation may 
help determine precise aetiology(27). Heart failure aetiology varies geographically and has 
varied over time with a shift in relative contribution of hypertension and rheumatic valvular 
disease towards coronary artery disease. Whilst coronary artery disease is a more dominant 
individual risk factor than hypertension, the population-attributable risk for the latter is still 
more influential(28, 29). Data describing the epidemiology of heart failure in the developing 
world are scarcer; endocardial diseases, trypanosomal infections and rheumatic heart disease 
are undoubtedly more prevalent. That said, the epidemiological transition to a more “western” 
lifestyle, atherosclerotic coronary artery disease is rapidly emerging as a dominant player(30). 
 
The progression of LVSD through maladaptive remodelling is a complex multi-system 
process involving local recurrent injury, autocrine processes and molecular adaptations, 
enhanced apoptosis and systemic processes, including neurohormonal activation and increased 
oxidative stress. This myriad of insults leads to progressive structural and functional changes 
in the heart leading to both electrical and mechanical dysfunction (Figure 1-3)(6).  
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Figure 1-3:  Pathophysiology of heart failure as a result of left-ventricular systolic 
dysfunction. Reproduced with permission from McMurray JJ et al(31).  
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1.1.7 Abnormalities of haemodynamics and vascular function in heart failure 
 
Symptomatic heart failure with reduced ejection fraction is characterised by the development 
of progressive cardiac dysfunction with concomitant functional abnormality of other tissues 
and organs. These processes are a consequence of local - autocrine and molecular adaptation - 
and systemic events such as neurohormonal activation, sympathetic nervous system activation 
and inflammation(31). Left ventricular systolic dysfunction progresses gradually, often 
beginning with an index myocardial injury such as acute myocardial infarction. This leads to a 
progressive loss of functioning myocytes. Loss of cardiac function occurs as a product of 
ventricular remodelling, through which ventricular geometry, dimensions and function are 
altered. Remodelling consists of a multitude of maladaptive pathophysiological processes 
including myocyte hypertrophy, necrosis and apoptosis and myocardial interstitial fibrosis and 
is exacerbated by activation of neurohormonal and inflammatory pathways(4, 32). The 
remodelling process may persist despite any further discrete myocardial injury. Many of these 
systems act synergistically, reinforcing each other.  
 
The Frank-Starling law describes the intrinsic attempt to maintain stroke volume during acute 
cardiac injury(33). This adaptative phenomenon is evident early after index injury. Reduction 
in stroke volume leads to elevated left ventricular end-diastolic pressure and dimension. This 
in turn leads to increased force of ventricular contraction, thus helping to maintain cardiac 
output. This is characteristic of the law of heterometric autoregulation – stretch of the cardiac 
myocytes leads to increased force of contraction. In addition to structural and molecular 
abnormalities, retention of water and sodium in the vasculature and venous vasoconstriction  - 
through extrinsic neurohormonal activation – increase preload in an attempt to maintain left 
ventricular filling pressure.  The same extrinsic processes promote arterial stiffness leading to 
increased afterload and progressive ventricular dysfunction(34).  
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Heart failure is associated with chronic peripheral vasoconstriction – both venous and arterial 
– through sympathetic nervous system activation, neurohormonal activation   and endothelial 
dysfunction(35-37). This contributes to reduced tissue perfusion, impaired pulmonary 
vasodilatation and resultant reduction in exercise capacity. Chronic hypo-perfusion promotes 
skeletal muscle ischaemia leading to inflammation and imbalance of reactive oxygen species. 
Endothelial dysfunction – characterised by reduced bioavailability of NO and enhanced 
vasoconstriction in response to exercise – is described in all vascular beds(37, 38). It is 
proportionate to severity of heart failure and predictive of adverse events(39, 40). Direct in 
vivo measurement of NO bioavailability in humans is difficult; as such vasodilator activity 
such as flow-mediated dilatation, laser Doppler imaging and quantification of NO-related 
compounds are measured as surrogates(41, 42). Vascular dysfunction is not restricted to the 
endothelium; investigators have demonstrated impaired micro-vascular responses to 
endothelium-dependent and independent vasodilators in patients with heart failure(43, 44).  
 
Few studies have directly addressed regional and organ haemodynamics in chronic heart 
failure(45, 46). The lack of experimental data reflects technical limitations in the study of 
regional haemodynamics  - particularly the need for invasive procedures. Most studies have 
been performed by means of indirect techniques such as venous occlusion plethysmography 
and radioisotope clearance studies(38).  Resistance to blood flow in any tissue is directly 
related to vascular smooth muscle tone and both intrinsic and extrinsic stressors such as 
vascular remodelling and neurohormonal activation(47). Reduction in cardiac output is 
accompanied by reduced blood flow to most regions. Renal function tends to fall in direct 
proportion to cardiac output but at extreme levels appears to plateau through protective 
autoregulation(46). Conversely, hepatosplanchnic blood flow is strongly correlated to cardiac 
output but not protected by autoregulatory mechanisms. Skeletal muscle blood flow is 
similarly proportionate to cardiac output; thus contributing to fatigue and exercise intolerance 
typical of the heart failure syndrome(48).  
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Augmenting ventricular systolic function or regional haemodynamics would appear to be an 
attractive therapeutic strategy but is limited in evidence-base and largely restricted in clinical 
practice to acute decompensated heart failure with hypoperfusion. Choice of agents includes 
sympathomimetics (e.g. dopamine, dobutamine, and epinephrine), phosphodiesterase 
inhibitors (e.g. milrinone, enoximone) or calcium sensitizers (e.g. levosimendan). Although 
effective in enhancing contractility, these agents (particularly sympathomimetics) have the 
unwanted effects of increasing myocardial oxygen consumption, promoting myocyte calcium 
loading and accelerating cell death, with the net effect of inducing maladaptive remodelling 
and promoting tachyarrhythmia. In fact, there is concern that inotropic therapy (particularly 
when administered chronically) may increase mortality in heart failure(49-51). 
 
Vasodilator therapy can influence central and regional haemodynamics in heart failure.  
Hydralazine and the alpha-adrenoreceptor antagonist prazosin significantly augment cardiac 
index and stroke volume whilst reducing pulmonary artery capillary pressure (a measure of 
left ventricular filling pressure) in patients with chronic heart failure(52). Both hydralazine 
and prazosin elicit significant improvements in resting forearm blood flow whereas 
hydralazine alone reduced renal vascular resistance with concomitant increase in renal blood 
flow. These and other data suggest sustained haemodynamic effects may be seen with chronic 
vasodilator – particularly hydralazine – therapy(53, 54).  Exercise capacity – measured by 
peak oxygen consumption (VO2) is strongly correlated to cardiac output. Nevertheless 
selectively augmenting regional organ haemodynamics and cardiac output neither improves 
outcome or symptoms (such as exercise intolerance) In a small study in patients with heart 
failure, hydralazine increased maximal exercise ± 105 versus 779 ± 82 ml/min) but had no 
effect on peak VO2(55). Based on experience from clinical trials there is clear dissociation 
between haemodynamics and other pathophysiological concepts in heart failure(56). 
Haemodynamic variables are not adequate surrogate end points for symptoms or outcome(57). 
Indeed some positively inotropic medications, which result in marked improvements in 
haemodynamic parameters, are associated with harm.  
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1.1.8 Oxidative stress in heart failure 
 
There is an increasing body of evidence suggesting that oxidative stress is involved in the 
pathogenesis of heart failure(4). Heart failure is characterised by the activation of a cascade of 
processes resulting in an imbalance between bio-available nitric oxide and harmful reactive 
oxygen species (ROS) (the so-called nitroso-redox imbalance). These pro-oxidant processes 
include pro-inflammatory cytokine activation, mitochondrial dysfunction, recurrent hypoxia 
and activation of the renin-angiotensin system associated with increased activity of NAD(P)H 
oxidase in blood vessels, largely through the effects of angiotensin-II(33). Other sources of 
enhanced ROS generation include NOS3 itself and xanthine oxidase(58, 59). The pro-oxidant 
state contributes to myocyte apoptosis and necrosis, endothelial dysfunction and remodelling.   
 
Several markers of ROS burden are elevated in heart failure including: urinary biopyrrins 
(derived from the oxidative metabolism of bilirubin); urinary isoprostanes, 8-epi 
prostaglandin-F-α and plasma malonyldialdehyde (markers of lipid peroxidation), and plasma 
reduced (GSH) and oxidised glutathione (GSSH) (60-63).  Elevated markers of ROS also 
contribute to the severity of myocardial dysfunction. In addition, urinary byopyrrins have been 
found to be elevated in proportion to severity of LVSD and NYHA functional class(60). 
Similarly, other markers of oxidative stress have been shown to be elevated in proportion to 
the severity of heart failure and positively correlate with markers of neurohormonal activation 
and inflammation(62, 63). However these are global measurements of oxidative stress, which 
may not always detect localised changes within the heart. Hyperuricaemia, as a consequence 
of increased activity of xanthine oxidase (a critical component of nitroso-redox balance) is a 
biomarker of oxidative stress in heart failure(59). Levels are a marker of deranged oxidative 
metabolism and influenced by hyperinsulinaemia, inflammatory cytokine activation and 
endothelial dysfunction; all of which are present in heart failure. It is debatable whether uric 
acid merely reflects the degree of immune activation (a so called ‘danger signal’) and tissue 
damage or has itself, a direct pathophysiological role. Nevertheless hyperuricaemia appears to 
have prognostic relevance(64-66).  
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Inhibition of xanthine oxidase is an attractive target in addressing nitroso-redox balance in 
cardiovascular disease. In a small randomised-controlled trial of 66 patients with IHD and left 
ventricular hypertrophy, high dose (600mg per day) allopurinol regressed LV mass with a 
parallel improvement in endothelial function assessed by flow-mediated dilatation(67). 
Allopurinol (at a more conventional dose of 300mg per day) improved endothelial function – 
assessed by forearm venous occlusion plethysmography in a group of 11 patients with heart 
failure(68). A subsequent publication by the same group demonstrated a dose-response 
relationship between allopurinol and its effects on endothelial dysfunction(69). Translation of 
these surrogate markers to tangible clinical improvements has been less clearly defined. The 
primary metabolite of allopurinol is oxypurinol. The Oxypurinol Compared With Placebo for 
Class III to IV New York Heart Association Congestive Heart Failure (OPT-CHF) Trial tested 
whether oxypurinol produces clinical benefits in patients with moderate-severe heart 
failure(70). 405 patients treated with optimal medical therapy (including a beta-blocker in 
92%) were randomized to receive oxypurinol 600 mg once daily or placebo for 24 weeks. 
Efficacy was assessed using a composite end point comprising HF morbidity, mortality, and 
quality of life. The primary endpoint was not met. The absence of clinical efficacy may relate 
to the low dose. The 600 mg dose of oxypurinol has a relative bioavailability equivalent to just 
81 mg of allopurinol(71). In hypothesis-generating sub-group analyses those patients with 
highest baseline levels of uric acid appeared to receive clinical benefit. 
 
The benefits of neurohormonal blockade with ACE inhibitors, angiotensin-II-receptor blockers 
and beta-blockers are well described(5). A component of this benefit may be derived from 
addressing the associated nitroso-redox imbalance. The magnitude of said benefit remains 
uncertain.  In animal models of heart failure, cardiac protection is observed with anti-oxidant 
treatment(72, 73).  However, in human clinical studies, the evidence is less compelling. Whilst 
short-term treatment with inotropic support improves markers of oxidative stress in parallel 
with inflammatory indices, this contrasts with a recent study of the optimal combination of an 
angiotensin-II-receptor blocker with an ACE inhibitor and beta-blocker in chronic heart 
failure(74, 75). Although this combination significantly decreased validated heart failure 
biomarkers NT-proBNP (N-terminal pro B-natriuretic peptide) and CRP (C-reactive protein), 
there was no effect on markers of oxidative stress. This potentially indicates that other 
mechanisms, independent of the renin-angiotensin system driving the pro-oxidative state, 
could be applicable therapeutic targets. 
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1.2 Hydralazine: clinical efficacy 	  
1.2.1 Historical background and medical use 
 
Hydralazine is part of the imadazoline family of compounds, discovered by Alfred Ladenburg 
in 1888 at the University of Breslau and first purported as an anti-hypertensive and vasodilator 
agent in 1951 in work by Ciba Laboratories(76).  Hydralazine is used to treat severe 
hypertension and in particular, pregnancy-associated hypertension(77). It is not considered a 
first line drug for treating hypertension because it causes reflex sympathetic activation  - 
through the baroreceptor reflex – leading to an unfavourable rise in heart rate and cardiac 
output (which may lead to myocardial ischaemia in patients with coronary artery disease). 
Treatment with hydralazine may also increase plasma renin concentration, leading to fluid 
retention. Hydralazine has also been recently used as a treatment for myeloproliferative 
conditions, including chronic myeloid leukaemia, through its capacity as a DNA 
methyltransferase inhibitor (which may also potentiate drug-induced lupus)(78).  
 
1.2.2 Biochemistry 
 
Hydrazine [1-hydrazinophthaline] hydrochloride (figure 1-4) is a synthetic compound 
prepared by the action of hydrazine hydrate on 1-chloro or 1-phenoxypthalazine.  Its 
bioavailability is variable ranging from 50-90% of a single oral dose. Depending on the dose, 
peak plasma levels occur from 0.3-1.0h after administration(79, 80). Hydralazine is well 
absorbed through the gastrointestinal tract and undergoes first pass metabolism, which is 
determined by the acetylator phenotype. As such, different bioavailability patterns are 
expected: most notably greater in slow acetylators than fast acetylators. The prevalence of the 
slow-acetylator phenotype among American and European Caucasians and African Americans 
is around 50%(81). Because the acetylated compound is inactive, the dose necessary to 
produce a systemic effect is higher in fast acetylators. N-acetylation of hydralazine occurs in 
the bowel and/or the liver. The half-life of hydralazine is 1 hour and its systemic clearance is 
approximately 50ml/kg/min.  
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Hydralazine rapidly combines with circulating α-keto-acid to form hydrazones; the major 
metabolite recovered from plasma is hydralazine-pyruvic-acid-hydrazone. This metabolite 
possesses a longer half-life than hydralazine but does not appear to be active. Hydralazine’s 
peak concentration in plasma and peak effects occurs within 30-120 minutes following 
administration. Although its half-life is approximately 1 hour, the duration of its effect can last 
for 12 hours. After stabilisation with multiple daily doses, a twice-daily dose regimen can be 
effective. Slow acetylators require a lower dose. For heart failure, the recommended doses are 
higher(82).  
 
 
Figure 1-4: chemical structure of hydralazine hydrochloride.  
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1.2.2 The V-HeFT studies 
 
In 1986 the vasodilator in heart failure (V-HeFT-I) study was the first placebo-controlled 
clinical trial to study the effect of vasodilator therapy on survival in patients with chronic heart 
failure and was, in fact, the first therapeutic approach shown to improve heart failure 
survival(83). This study randomised 642 men with mild to moderate heart failure to placebo, 
the alpha-adrenoreceptor antagonist prazosin or to the combination of hydralazine and 
isosorbide dinitrate (ISDN) added to standard therapy (at that time) with a diuretic and 
digoxin. These patients were treated at a time when the benefits of angiotensin-converting 
enzyme (ACE) inhibitors, beta-blockers and mineralocorticoid-receptor antagonists were not 
known. Two years after randomisation, survival in the hydralazine-ISDN group was 
significantly enhanced than in the placebo group (P =0.028) (Figure 1-5).  Hydralazine-ISDN 
also increased exercise capacity and left ventricular ejection fraction compared to the placebo 
group. Interestingly, these benefits were despite the fact the prazosin had a greater BP 
lowering effect and was one of the first indicators that the clinical benefits of hydralazine 
might exceed simply that of BP reduction. Mortality in the prazosin group was not different 
from the placebo group.  
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Figure 1-5: Kaplan-Meier survival curves from Ve-HeFT-I study. Reproduced with 
permission from Cohn JN et al(83).  
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The second V-HeFT-II study compared the efficacy of hydralazine-ISDN with that of the 
angiotensin-converting-enzyme inhibitor enalapril(84). 804 men in NYHA II-III functional 
status were randomised to hydralazine-ISDN or enalapril in addition to standard therapy with 
a diuretic and digoxin.  Two years after randomisation all-cause mortality was 18% in the 
enalapril group as compared with 25% in the hydralazine-ISDN group (P=0.016). A clear 
early difference was observed, with superiority in the enalapril arm, which produced a 27% 
relative risk reduction in mortality (attributed to a reduction in sudden cardiac death). A 
similar 2-year mortality in the H-ISDN group (25%) compared with Ve-HeFT-I indicated that 
the patients involved were just as sick. Because this drug combination was shown to be less 
effective than an ACE inhibitor it was little used.  
 
1.2.3 The A-HeFT study 
 
Retrospective analyses of both V-HeFT-I and V-HeFT-II suggested that African-Americans 
derived benefit from the hydralazine-ISDN combination whereas Caucasians did not(85, 86). 
Conceptually, this analysis was based on a series of observations that suggested a relative 
deficiency of nitric oxide in African Americans, though the exact nature of the defect(s) has 
not been established. The biological plausibility of inter-racial differences in drug efficacy is 
supported by epidemiological and clinical trial data, particularly in hypertension. 
Cardiovascular disease is the leading cause of death among African Americans, and the 
incidence (and mortality) of both IHD and stroke is higher compared to Caucasian 
Americans(87). African Americans are more likely to develop hypertension earlier in their 
lifetime and have a more severe phenotype. Complex environmental and epigenetic 
interactions may explain this phenomenon, particularly socio-economic deprivation. 
Nevertheless, there are robust data demonstrating variations in the renin-angiotensin system in 
African American patients and clinical efficacy of anti-hypertensive agents(88-90). In addition 
to variations in endothelial function and nitric oxide-mediated vascular responses, African 
American patients have a less significant blood pressure response to renin-angiotensin 
inhibitors and beta-adrenoreceptor antagonists(90). Contemporary clinical practice guidelines 
reflect these data and recommend calcium-channel antagonists and thiazide diuretics as first 
line therapy(91).  
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The African-American Heart Failure (A-HeFT) trial was undertaken and randomised 1050 
patients who were NYHA class III and IV to receive a fixed dose combination of hydralazine-
ISDN three times daily(86). Critically, in this trial, the patients were already treated with the 
optimal currently available drug therapy, including an ACE inhibitor (70%), beta-blocker 
(74%), and, in many cases, a mineralocorticoid-receptor antagonist (39%). The initial dose of 
treatment was 20mg ISDN/37.5mg hydralazine administered three times daily, increased to a 
target of 40mg/75mg.  However, the trial was discontinued prematurely at a median follow-up 
of 10 months following a significant reduction in all-cause mortality (RRR 43%, ARR 4.0% 
NNT 25, P=0.01) (Figure 1-6). A composite endpoint was used, combining mortality, quality 
of life (as measured on the Minnesota Living with Heart Failure Questionnaire) and time to 
first hospitalisation; each component was statistically significant in favour of the combination 
therapy. This fixed-dose combination is approved by the US Food and Drug Administration 
(FDA) and specifically licensed in this heart failure indication as BiDil©, produced by Arbor 
Pharmaceuticals Inc(92).  
 
The magnitude of these defects parallels – on in some cases – exceeded almost all other 
double-blind placebo-controlled trials in heart failure. However, whilst providing an 
opportunity to advance medical therapy for heart failure, the controversial approval based on 
race by the US FDA has negatively impacted adoption by practitioners. Similarly, the 
relatively small study size, the very selected population studied and the trial’s early 
termination have left some uncertainty about the value of this combination therapy, especially 
in non African-American patients. Nevertheless, it is widely believed that these incremental 
benefits could be achieved in patients of other ethnicities who remain symptomatic despite 
optimal neurohormonal therapy. Although the precise mechanism of action is largely 
unexplained, the combination of hydralazine-ISDN results in vasodilatation through increased 
production of endothelial nitric oxide and has thus been considered a “nitric oxide enhancing” 
therapy. This approach may provide incremental benefits in patients already receiving 
standard neurohormonal therapies by producing further vasodilatation and directly targeting 
endothelial dysfunction, a hallmark of the heart failure syndrome(93).  
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Figure 1-6: Kaplan-Meier survival curves comparing isosorbide dinitrate (ISDN)-
hydralazine (HYD) combination with placebo in A-HeFT study. Reproduced with 
permission from Taylor et al(94). 
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1.2.4 Contemporary clinical practice guidelines  
 
Current European guidelines recommend that other than for African Americans, the main 
indication for hydralazine-ISDN is as a substitute in patients with intolerance to an ACE 
inhibitor or an angiotensin-receptor antagonist (ARB) (Class IIb, level of evidence B)(5). 
Hydralazine-ISDN should also be considered as an additional treatment in African Americans 
and considered on an empirical basis for other patients who remain symptomatic on other 
proven therapies (including a mineralocorticoid receptor antagonist) (Class IIb, level of 
evidence B). Neither drug on its own has been demonstrated to be beneficial in heart failure. 
The main dose-limiting adverse effects are headache and dizziness. A rare adverse effect of 
higher doses of hydralazine, especially in slow acetylators, is a systemic lupus erythematosus-
like syndrome, which is likely to result from inhibition of DNA methylation(95).  
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1.3 Mechanism of action of hydralazine: current knowledge 
 
Hydralazine is a potent vasodilator that has been in clinical use for nearly six decades. Despite 
that, its mechanism of action remains poorly understood. Hydralazine appears to act as a 
dominant arterial vasodilator with potential mild inotropic properties, which is thought to be 
due to reflect activation of the sympathetic nervous systems(54, 96). This inotropic action 
might be responsible for a less favourable effect on myocardial oxygen consumption thereby 
counteracting the unloading effects of vasodilatation(97, 98). Most evidence suggests an 
intracellular mechanism, possibly with involvement of altered calcium balance in vascular 
smooth muscle cells by inhibition of calcium release from the sarcoplasmic reticulum. This 
may be secondary to inhibition of membrane ATPases, kinases or ion channels or a membrane 
hyperpolarisation effect(99-101). The scarce functional studies undertaken in human blood 
vessels indicate a dominant arterial effect but do not provide mechanistic insight(102).  
 
Hydralazine preferentially decreases vascular resistance in the coronary, cerebral and renal 
circulation with a smaller effect in skin and muscle. It does not appear to utilise established 
vasodilator mechanisms such as alpha-adrenoceptor antagonism or calcium entry blockade. It 
appears to have a direct action on vascular smooth muscles, which may not be endothelium 
dependent. Nevertheless, its action may be potentiated by the presence of endothelium in some 
models suggesting a further indirect effect on smooth muscle(103). In addition to the 
vasodilator role of hydralazine, it has been shown to prolong the effects of ISDN in 
experimental and clinical models(104, 105). Hydralazine appears to be an effective 
antioxidant and, by reducing antioxidant stress, protects against nitric oxide degradation(106). 
It thus may have beneficial effects in states where endothelial dysfunction predominates.   
 
Identification of the mechanism of action of hydralazine in human blood vessels may allow 
the design of drugs with a comparable prognostic benefit which avoiding its documented 
adverse effects. Studies to date have failed to produce conclusive evidence of the mechanism 
of action of hydralazine. The variety of animal models used in the literature and the varying 
techniques used could explain this disparity. There have been no comprehensive investigations 
of the commonly examines vasodilator systems in human blood vessels, particularly in the 
contemporary era.   
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1.3.1 Role of potassium channels 
 
Membrane hyperpolarisation due to activation of K+ channels is a recognised important mode 
of action for several vasodilators including synthetic openers of ATP-sensitive K+ channels 
such as cromakalim, pinacadil and minoxidil(107). Hydralazine has been reported to produce 
membrane hyperpolarisation in isolated rabbit femoral arteries(101, 108). In these studies, 
hydralazine preferentially relaxed contractions induced by moderately raised K+ (20mM) 
compared with those induced by highly elevated K+ (124mM). This effect profile is 
characteristic of drugs acting by K+ channel opening and associated membrane 
hyperpolarisation(109).  Conversely, the anti-diabetic drug glibenclamide, which is an 
effective blocker of ATP-sensitive K+ channels, has failed to influence hydralazine-induced 
vasodilatation in rabbit femoral arteries. Likewise, Ba2+, also failed to influence to relaxant 
effect in this study(108).  These results suggest that hydralazine does not exert vasodilatation 
by activation of ATP-sensitive K+ channels unlike alternative vasodilators. The membrane 
hyperpolarisation identified must therefore be explained by the activation of alternative 
channels.  
 
High-conductance Ca2+ activated K+ channels (BKCa) serve as a negative feedback mechanism 
limiting the depolarisation and Ca2+ increasing effects of vasoconstrictors. Opening of these 
channels allows K+ flux out of the cell leading to a change in membrane potential in a 
hyperpolarising direction, thus inducing vasodilatation. There are also recent data suggesting 
that such channels may be activated via the nitric-oxide (NO) cyclic guanosine 
monophosphate (cGMP) pathway, which may modulate the vasodilator response to both 
exogenous nitroso-vasodilators and endogenous receptor-mediated release of NO(110, 111).  
This effect may - in part - be through an effect on endothelial superoxide production elicited 
by changes in the membrane potential through BKCa channel activation.  The effect of 
hydralazine on these channels has been investigated in animal studies; both ex vivo and in vivo 
studies in isolated porcine coronary arteries and perfused rabbit hearts demonstrated that the 
blockade of these channels attenuated the vasodilator effect of hydralazine(100). This result 
can be demonstrated by the use of selective BKCa channel inhibitors such as 
tetraethylammonium (TEA) and iberiotoxin. This effect appears to be attenuated by arterial 
endothelial removal suggesting that hydralazine response may be partly mediated through 
such channels in the endothelium. A similar effect was demonstrated in studies of nitro-
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glycerine mediated vasodilatation in human arteries, but not veins(111). Conflicting results 
were seen in a study of the effects of hydralazine in rabbit aorta and pulmonary arteries(99).  
Hydralazine failed to alter the potassium currents recorded from isolated smooth muscle cells 
using a whole-cell patch-clamp technique. There was no apparent effect on membrane 
potential. The authors of this study acknowledged that hydralazine may act differently in other 
vascular preparations. They suggested that potassium channel blockade (by iberiotoxin or 
TEA) influenced the response to hydralazine by promoting membrane depolarisation and 
enhancing Ca2+ influx through voltage-operated calcium channels. This theory is partly 
supported by the lack of effect of hydralazine on Ca2+ influx or contractile responses mediated 
by Ca2+ influx in earlier studies(112). 
 
1.3.2 Sarcoplasmic reticulum  - role of calcium 
 
The vascular smooth muscle cell (VSMC) sarcoplasmic reticulum (SR) is an attractive site of 
action for hydralazine. Hydralazine has been shown to induce a fall in intracellular Ca2= 
concentration available for contraction, and to inhibit contractions evoked by caffeine (which 
directly stimulates release of Ca2+ from SR)(112, 113).  Hydralazine may act by inhibiting the 
release of Ca2+ evoked by inositol 1,4,5 triphosphate (IP3)(112, 113). The alpha-adrenergic 
agonist vasoconstrictor phenylephrine is thought to induce tonic tension through sustained and 
oscillating Ca2+ influx through permeable channels in the VSMC membrane. The release of 
SR Ca2+ mediated by intracellular IP3 is thought to underlie the initial, usual transient phase of 
tension. Therefore, hydralazine should inhibit this initial phasic response in addition to tonic 
tension. Hydralazine was equally effective at inhibiting both phasic and tonic contractions 
evoked by PE and IP3 in the Ellershaw study of rabbit aorta and pulmonary artery(99). 
Hydralazine had similar efficacy in reducing caffeine induced contraction and VSMC 
intracellular Ca2+ concentration via the caffeine-sensitive Ca2+ activated Ca-release (CICR) 
channel(99).  There was, however, a loss of effectiveness when SR Ca2+ stores were 
pharmacologically depleted with ionomycin, further supporting a role for the SR in 
hydralazine action.  It is unclear whether this disrupted Ca2+ balance is due to direct 
antagonism of IP3 or CICR mediated Ca2+ release or was, in fact, secondary to an event such 
as membrane hyperpolarisation or elevation in cGMP levels. It does not, however, appear to 
be endothelium dependent in this rabbit model.  
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1.3.3 Role of second messengers 
 
Studies in non-vascular smooth muscle suggest that hydralazine may activate guanylate 
cyclase leading to increased cGMP levels. This hypothesis is yet to be proven as there 
continues to be disparity between studies(103, 114, 115). There is evidence that hydralazine 
activates this system in the human placental circulation and in women with pre-eclampsia(116, 
117). Another, as yet, unresolved issue is the dependence of hydralazine action on intact 
vascular endothelium. The issue is complex, with evidence that hydralazine may normalise 
impaired endothelium-dependent relaxation elicited by acetylcholine in nitric-oxide deficient 
states. Supportive studies include that of Wei et al who investigated endothelium-dependent 
vasodilatation of hydralazine in porcine coronary arteries(103). Hydralazine-induced 
relaxation was not significantly affected by the presence of L-NOARG, an inhibitor of NO 
production, nor indomethacin, an eicosanoid inhibitor. In addition, hydralazine had no effect 
on cyclic adenosine monophosphate (cAMP) levels; rather it induced a 1.5-fold increase in 
cGMP levels in endothelium-intact arteries. NO did not appear to contribute to the 
endothelium-dependent relaxation because neither L-NOARG, nor haemoglobin, a chelator of 
NO, affected hydralazine-induced endothelium-dependant relaxation. Pre-treatment of arteries 
with actinomycin D, a transcription inhibitor significantly reduced the hydralazine-induced 
vasodilatation and increase in cGMP level. This did not affect ionomycin-induced relaxation, 
which stimulated the NO/cGMP system. This tends to suggest that the endothelium-dependent 
relaxation could be secondary to the immediate transcription of an unidentified organic 
molecule in endothelial cells. Basal cytosolic cGMP production was unchanged in the 
presence of hydralazine although it was increased in presence of phenylhydralazine.  
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1.3.4 Hypoxia-inducible factor activation 
 
Hydralazine has been known to disturb collagen biosynthesis for some time. It is thought to 
complex with enzyme-bound Fe2+ and thus inhibits enzyme activity - one such target being the 
protocollagen prolyl hydroxylase, thus preventing the formation of stable collagen fibers. 
Other members of this family include the prolyl hydroxylase domain enzymes (PHD), which 
regulate hypoxia inducible factor (HIF). In a novel study, inhibition of the PHD pathways by 
hydralazine rapidly activated the HIF system and produced vasodilatation through indirect 
release of NO. Additional potential mediators include endothelin-1 and vascular endothelial 
growth factor  (VEGF), which are likewise known to promote angiogenesis. In this study, the 
investigators demonstrated that hydralazine transiently activated the HIF system by inhibiting 
PHD enzyme activity(118). The results of this study therefore identified a potential molecular 
target for hydralazine activity.  
 
1.3.5 Interaction with reactive oxygen species 	  
 
The balance of endogenous and exogenously generated nitric oxide (NO) and vascular 
superoxide production is known to be important in both health and disease. Endothelial 
dysfunction is a common feature of cardiovascular disease, including heart failure, and has 
partly been attributed to the generation of increased vascular production of superoxide anions 
with the resultant inactivation of bioactive NO(119). Hydralazine appears to have the ability to 
affect a number of enzyme systems both in vivo and ex vivo.  In addition to a high affinity for 
cations such as Fe2+ and Cu2+, hydralazine as a carbonyl reactor has been shown to interact 
with pyridoxal phosphate and thus interferes with the function of this agent as an enzymatic 
cofactor(120). In general, however, enzyme inhibition is not considered to perform a role in 
hydralazine vasodilatation because, ex vivo, such high concentrations of hydralazine are 
required for effective inhibition. However, it is recognised that hydralazine readily 
accumulates in the vascular smooth muscle cell layer and thus physiologically exerts its 
effects at proportionally higher local concentrations(121).  
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Contradictory evidence comes from a study of hydralazine in an animal model of nitric-oxide-
deficient hypertension(122). Using Wistar rats, pre-treated with the NO synthase inhibitor L-
NAME, investigators examined the effects of hydralazine on superoxide formation and 
expression of endothelial NO synthase. The vasodilator response to acetylcholine was 
examined in intact aortic rings. Relaxation was attenuated in L-NAME treated animals; this 
response was normalised by hydralazine therapy. L-NAME treated animals exhibited 
increased levels of superoxide production, however, interestingly this was not improved with 
hydralazine therapy; nor was there a change in NO synthase production. In contrast, soluble 
guanylate cyclase expression was attenuated in L-NAME treated animals and nearly 
normalised with concomitant hydralazine therapy. The improvement of acetylcholine-induced 
relaxation therefore did not appear to involve modulation of NO/superoxide balance but 
instead increased soluble guanylate cyclase expression. These disparate findings could partly 
be explained by species difference in the oxidase(s) involved in superoxide formation.  
 
Another enzyme system of recent interest to my study is semicarbazide-sensitive amine 
oxidase (SSAO). This enzyme group appears to be ubiquitous in biology and is known to act 
via primary amine substrates to produce a variety of effects(123). It does not appear to be 
affected by the usual inhibitors of monoamine oxidase and is defined by its sensitivity to 
inhibition by the hydrazine derivative semicarbazide(124). In humans, SSAO predominates 
within vascular smooth muscle cells where it assumes a sub-cellular position. It appears to be 
partially glycosylated and contains a carbonyl group and Cu2+, making potential interaction 
with hydralazine biologically plausible. The breakdown products of SSAO are active and 
include hydrogen peroxide and aldehydes. Hydrogen peroxide can act as a powerful oxidant or 
as a signaling molecule depending on location and concentration. It is recognised that SSAO is 
associated with pathophysiological processes, in particular vascular endothelial damage. 
Elevated plasma levels of both enzyme and breakdown products are recognised in diabetes 
mellitus, heart failure, atherosclerosis and Alzheimer’s disease(125). As a hydrazine-
containing molecule, hydralazine strongly interacts with SSAO. Several studies have 
demonstrated that hydralazine-induced hypotension can be potentiated by pre-treatment with 
other hydrazine groups such as isoniazid. Initially these findings were attributed to central 
mechanisms of cardiovascular regulation, specifically a reduction in cerebral GABA following 
high-dose isoniazid therapy. However, lower doses have been demonstrated to potentiate 
hydralazine effects independently of cerebral GABA(126). This phenomenon has been further 
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demonstrated using SSAO substrates such as methylamine and benzylamine. Pre-
administration appears to enhance hydralazine hypotension and this associated with a 
reduction in the plasma concentration of the SSAO breakdown product hydrogen peroxide. 
Interestingly, this effect appears to be prevented by the peroxide scavenger catalase, 
suggesting that this species is involved in the hypotensive effects of hydralazine(127). The 
role of hydrogen peroxide in vascular regulation appears to be complex, and in fact it has been 
demonstrated to be both vasoconstrictor and vasodilator in various models.  
 
The postulated relationship of hydralazine with SSAO finds support from the in vivo 
accumulation of hydralazine in the vascular smooth muscle layer and the cellular location of 
this enzyme system(121). Other SSAO inhibitors lack this particular distribution and 
hydralazine is the only known drug for which its vasodilator effect could partly be attributed 
to vascular SSAO inhibition. This may, in part, explain the disparity between the contractions 
required to elicit an effect in vivo as opposed to ex vivo studies. The time lag of effect prior to 
the onset of hydralazine-induced hypotension in vivo may also plausibly reflect the latency of 
enzymatic interaction. Further supportive evidence of said anti-oxidant effect can be taken 
from a study investigating the effect of hydralazine on sodium nitroprusside (SNP) induced 
vasodilatation(128). In that study it was recognised that NAD(P)H oxidase may be involved in 
the reduction of SNP to nitric oxide in some animal models. More particularly, NAD(P)H 
oxidase appears to be inhibited by hydralazine and, in fact, co-administration of hydralazine 
with SNP led to a rightward displacement of CCRCs. This attenuation of vasodilatation was 
accompanied by a reduction in cGMP production, presumably through inhibition of NO 
formation. It is interesting to observe that the sensitivity of vessels to hydralazine-SNP-
attenuation appeared increased in those without endothelium. Vasodilator response to SNP is 
considered to be augmented in endothelium-denuded vessels in a manner analogous to 
denervation. Endothelium-intact vessels appear to be more resistant to the hydralazine-SNP-
attenuation thus supports the hypothesis that there is an additional endothelial source of 
oxidase, which is more resistant to hydralazine therapy. Further supportive evidence for a 
mechanistic interaction with reactive oxygen species can be gleaned from studies exploring 
the phenomenon of nitrate tolerance (discussed in Chapter 1.4.2 below).  
 
The potential antioxidant effects of hydralazine have – based on my knowledge - never before 
been examined in human blood vessels.  
	   53	  
1.4 Interaction with organic nitrates 
 
1.4.1 Mechanism of action of organic nitrates 
 
Synthesis of the organic nitrate nitro-glycerine was first reported in 1846.  20 years later, its 
use as an explosive agent became the source of Alfred Nobel’s landmark discovery. To quash 
the medical profession’s concerns regarding the ingestion of an explosive drug, it was later 
renamed glyceryl-trinitrate (GTN) and has been used as a vasodilator drug for the last two 
centuries.  Since then several other clinically relevant organic nitrates have been developed 
(Figure 1-7).  Organic nitrates contain the nitrooxy functional group (-O-NO2), almost all 
examples being aliphatic nitrates, owing to the presumed instability of the aromatic nitrate to 
rearrangement(129).  
 
 
Figure 1-7: Nitrosovasodilators 
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Organic nitrates must undergo intracellular metabolism in order to promote vasodilatation; a 
process often referred to as bio-activation. It is widely held that the biologically active product 
of biotransformation of organic nitrates is NO, and, thereafter, the activation of guanylate 
cyclase produces cGMP (130). In the past decade, substantial insight into this bio-activation 
process has been gained.   A substantial amount of information has been collated regarding the 
mechanisms underlying nitrate tolerance.  GTN is metabolised by at least two different 
pathways; first at high doses by a low-affinity pathway (via cytochrome P450) and, second at 
low doses by a high-affinity pathway (via aldehyde dehydrogenase (ALDH-2))(131).  
 
High potency nitrates such as GTN, pentaerythrityl-tetranitrate (PETN), and pentaerythrityl- 
trinitrate (PETriN) are activated by mitochondrial ALDH-2, yielding an NO-containing 
compound(132). This molecule activates soluble guanylate cyclase (sGC), which decreases 
cytosolic Ca2+ by promoting extracellular currents and increasing Ca2+ uptake to intracellular 
stores such as the sarcoplasmic reticulum.  The bio-activation of low potency nitrates such as 
isosorbide-dinitrate (ISDN), isosorbide-5-mononitrate (ISMN), glyceryl-dinitrate (GDN) and 
pentaerythrityl-dinitrate (PEDN) are most likely metabolised by P450 enzyme(s) in the 
endoplasmic reticulum (ER) directly yielding NO. The latter mechanism also metabolises high 
potency nitrates when they are administered at high concentrations (> 1 µM). (Figure 1-8). 
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Figure 1-8: Proposed mechanisms underlying bio-activation of organic nitrates. On the 
left, characterisation of the bio-activation of high-potency nitrates; on the right the low-
potency nitrates. Reproduced with permission from Munzel et al(131).  
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Sodium nitroprusside (SNP) appears to act as a direct NO donor in contrast to nitrates 
requiring bio-activation. SNP spontaneously releases NO, which is coordinated as a nitrosyl 
group liganded to iron in a square bipyramidal complex within its structure. NO appears to be 
released spontaneously at physiological pH from the parent compound(130). Multiple 
reducing agents, including NAD(P)H oxidase are implicated to catalyse the release of NO 
from SNP in the vasculature(133, 134). Clinical use of SNP is limited by need for parenteral 
administration, by means of the development of pharmacological tolerance and the potential 
development of thiocyanate toxicity with prolonged administration.  
 
1.4.2 Mechanism of nitrate tolerance 
 
The concept of nitrate tolerance is complex and not wholly understood. A number of vascular 
and extra-vascular phenomena have been observed and shown to compromise the long-term 
haemodynamic effects of organic nitrates(131). These include the so-called pseudo-tolerance 
arising through neurohormonal activation, intravascular volume expansion, and increased 
catecholamine and vasopressin production; events which have been recognised in heart failure 
patients receiving long-term nitrate therapy(135).   
 
The second concept of vascular tolerance relates to the intrinsic effects of nitrate therapy on 
vascular endothelium and vascular smooth muscle cells (VSMCs) and includes impaired 
nitrate biotransformation, increased vascular superoxide production, the desensitisation of 
sGC, increased sensitivity to vasoconstrictors and the uncoupling of endothelial nitric oxide 
synthase (NOS3) (Figure 1-9).  
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Figure 1-9: Molecular mechanisms of nitrate tolerance. Reproduced with permission 
from Munzel et al(131).  
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Oxidative stress and redox imbalance is thought to play a critical role in nitrate tolerance and a 
ROS-dependent interference with NO signalling is compatible with cross-tolerance with other 
nitrates such as ISDN and ISMN. Sage et al demonstrated that nitrate tolerance in patients is 
directly related to increased superoxide formation and consequent reduced GTN 
biotransformation in human blood vessels. Rings of saphenous vein and internal mammary 
artery were harvested at the time of elective coronary artery bypass surgery in patients treated 
for 24 hours pre-operatively with GTN (10µg/min intravenously)(136). Using lucigenin-
enhanced chemiluminescence, the harvested veins demonstrated an increased vascular 
superoxide formation in GTN-treated patients and a 40% reduction in 1,2-dinitroglycerin (a 
GTN bio-activation metabolite) measured by gas chromatography. Nitrates stimulate the 
vascular (particularly endothelial) production of peroxynitrite, a highly reactive intermediate 
generated from rapid, diffusion-limited reaction of NO with superoxide. Peroxynitrite can 
oxidise the eNOS cofactor tetrahydrobiopterin (BH4) to dihydrobiopterin (BH2) via 
intermediate formation of trihydrobiopterin (BH3) radicals(137). This may lead to 
dysfunctional eNOS activity; the so-called NOS uncoupling.  
 
In 1995, Munzel and colleagues defined a new molecular mechanism accounting for GTN 
tolerance and cross-tolerance(138). They identified that aortic segments from 3-day GTN-
exposed rabbits were tolerant to the vasodilator action of GTN ex vivo and exhibited cross-
tolerance to acetylcholine and the non-enzymatic stimulator of NO production SIN-1. 
Removal of the endothelium, however, markedly attenuated tolerance to GTN and cross-
tolerance to SIN-1, suggesting a substantial role of the endothelium in mediating tolerance. 
Other investigators have demonstrated this phenomenon(139). It was postulated that the 
endothelium was either releasing a vasoconstrictor molecule and/or that NO became 
chemically inactivated before it could stimulate sGC in VSMCs. In support of this hypothesis, 
superoxide levels in tolerant vessels were approximately twice that of controls, and were 
normalised by removal of the endothelium. Because diphenyleneiodonium acutely inhibited 
superoxide formation, a flavin-containing oxidase was suggested as the likely superoxide 
source. They subsequently detected an increased activity of membrane-bound 
NADH/NAD(P)H oxidase in tolerant vascular tissue(106).   
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Other investigators have implicated increased NAD(P)H oxidase activity in nitrate tolerance, 
both in animal and human models(140, 141).  Thus far, it is not known whether nitrate 
tolerance increases the expression of subunits critical for NAD(P)H oxidase activity or 
whether it stimulates an association of cytosolic subunits with the membrane-bound 
cytochrome b5/p22phox oxidase components.   
 
Other hypotheses exist and the published, literature available in this regard is considerable. 
My research of these works leads me to conclude that tolerance may not be a class effect, and, 
as yet a unifying hypothesis has not been established.  
 
 
1.4.3 Clinical evidence of interaction 
 
Hydralazine co-treatment has been shown in clinical studies to prolong the vasodilator effect 
of nitrates, though the mechanism of this effect in humans remains uncertain(105).  In certain 
studies, the addition of hydralazine to a nitrate causes a greater effect on the reduction in 
cardiac filling pressures than can be achieved by hydralazine alone(142, 143). This interaction 
remains poorly understood.  
 
 
1.4.4 Experimental evidence of interaction  
 
Enhanced vascular formation of superoxide has been implicated in the development of nitrate 
tolerance. Nitro-glycerine-induced increase in superoxide production can be inhibited by 
dipheyleneiodonium; this infers that the anion is flavin-derived(138). A major source of such 
oxygen radical production is a membrane-bound flavin-containing NADH/NAD(P)H-
dependent oxidase which is regulated  in vivo  and ex vivo by angiotensin-II(144). This 
hypothesis has been explored by Munzel and colleagues(106). This study investigated the 
effect of nitrate therapy on oxidase-system activation and the effect of hydralazine on 
superoxide production in rabbits. Rates of superoxide production were more than two-fold in 
animals treated with nitrate. Concomitant in vivo treatment with hydralazine significantly 
reduced superoxide production. This effect was negated by the addition of KCl thereby 
suggesting that altered membrane potential might modulate production of superoxide.   
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In vessel homogenates, hydralazine treatment decreased NADH-dependent oxidase in animals 
treated in vivo; however, the same effect was not observed when incubated ex vivo.  This 
suggests that hydralazine had no direct scavenging effect. Hydralazine was only effective 
when administered in vivo or to intact vascular rings. Potential explanations include the 
prevention of assembly of the oxidase rather than inhibition or inhibition by membrane 
hyperpolarisation.  
 
Hydralazine has also been shown to possess powerful, peroxynitrite-quenching properties, 
which could explain - in part - its attenuation of experimental nitrate tolerance(145). Daiber 
and colleagues created in their study an in vivo state of nitrate tolerance with prolonged (3 
day) subcutaneous administration of GTN to Wistar rats.  The antioxidant effects of 
hydralazine were thereafter examined in cell free systems, cultured VSMCs, isolated cardiac 
mitochondria, and vascular preparations (aortic rings). Superoxide production was measured 
using lucigenin-enhanced chemiluminescence and dihydroethidium fluorescence. Their 
conclusions were that hydralazine appeared to decrease superoxide production in a dose-
dependent manner. Additionally, hydralazine inhibited peroxynitrite-mediated nitration of 
phenols in VSMCs. These data implied that hydralazine was a potent ROS scavenger. 
Surprisingly, the anti-oxidant effect of hydralazine, and its potential role in nitrate tolerance, 
has never been directly characterised in human blood vessels.  
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1.5 Summary and aims of thesis 
 
The conflicting literature available on the effects of hydralazine may be partly explained by 
the diverse animal models examined, as inter / intra-species variability in enzyme isoforms, 
channel distribution and second messengers exist. Likewise a novel and, as yet, unidentified 
mechanism may contribute to the action of hydralazine.  
 
In this thesis my aim was to characterise the actions of therapeutic concentrations of 
hydralazine in arteries and veins of various calibre, taken from patients with low ejection 
fraction heart failure secondary to coronary artery disease. From the currently available 
evidence I postulated that hydralazine would augment the response to vasodilators acting 
through the cyclic GMP pathways and that this effect would be greater in arteries than veins. I 
also set out to demonstrate that hydralazine would attenuate both basal and stimulated vascular 
superoxide production. Such a conclusion would support the existing available data supporting 
that hydralazine prevents nitrate tolerance through modulation of the nitroso-redox system; 
moreover, my experiments would be the first such studies conducted using human blood 
vessels.  
 
Chapter 3 focuses on the direct vasodilator effect of hydralazine in large and small calibre 
blood vessels.  The hypothesis was that hydralazine has a direct vasodilator effect on both 
arteries and veins taken from patients with LVSD and CAD and that this effect would be 
greater in arteries.  
 
The aims of Chapter 3 were therefore: 
 
1. To determine the comparative vasodilator effect of hydralazine on human internal 
mammary artery and saphenous vein using therapeutically relevant concentrations of 
hydralazine.  
2. To determine the vasodilator effect of hydralazine on human subcutaneous resistance 
arteries using therapeutically relevant concentrations of hydralazine.  
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Endothelial dysfunction is understood to be central to the pathophysiology of cardiovascular 
disease – particularly heart failure. The available literature suggests that hydralazine leads to 
activation of guanylate cyclase (through endothelial NO production). Chapter 4 focuses on a 
series of experiments aimed to determine if ex vivo treatment with hydralazine augmented 
endothelium-dependent vasodilatation (with the stable analogue of acetylcholine, carbachol) in 
human blood vessels taken from patients with LVSD and CAD.  
 
The aims of Chapter 4 were therefore: 
 
1. To determine if hydralazine augments the vasodilator response to the endothelium-
dependent vasodilator carbachol in large calibre blood vessels. 
2. To determine if hydralazine augments the vasodilator response to carbachol in 
subcutaneous resistance arteries.  
 
Chapter 5 focuses on the interaction between hydralazine and clinically relevant 
nitrosovasodilators. The therapeutic synergy of ISDN and hydralazine in patients with heart 
failure has been attributed to favourable haemodynamic effects as well as the purported ability 
of hydralazine to reduce nitrate tolerance.  
 
The aims of Chapter 5 were therefore: 
 
1. To determine if hydralazine augments the vasodilator response to clinically 
relevant nitrosovasodilators (GTN, SNP and ISDN) in human blood vessels taken 
from patients with LVSD and CAD.  
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Chapters 6 directs attention to oxidative stress and the production of vascular superoxide – 
understood to be one of the major mechanisms underlying endothelial dysfunction in heart 
failure and considered integral to the mechanism of nitrate tolerance in clinical practice. 
Hydralazine has purported anti-oxidant properties although the direct effect of hydralazine on 
the production of vascular superoxide has never been investigated before in human blood 
vessels. The hypothesis is that hydralazine would reduce basal superoxide production in large 
calibre blood vessels taken from patients with LVSD and CAD.  
 
The aims of Chapter 6 were therefore: 
 
1. To assess the effect of hydralazine on basal superoxide production in internal 
mammary arteries and saphenous veins 
2. To assess the relative potency of hydralazine on internal mammary arteries and 
saphenous veins.  
3. To assess any apparent dose-response to hydralazine on basal superoxide 
production.  
 
In Chapter 7 the interaction between neurohormonal activation – particularly production of 
angiotensin II – and oxidative stress are discussed. I examined if hydralazine attenuated 
angiotensin-II mediated superoxide production. Angiotensin-II stimulates superoxide 
production through activation of NAD(P)H oxidase in the vasculature. This is an important 
therapeutic target for neurohormonal antagonists but is also a purported enzyme system 
through which hydralazine may interact.  
 
The aims of Chapter 7 are therefore: 
 
1. To determine if co-incubation of human IMA vessels with hydralazine attenuated 
angiotensin-II stimulated superoxide production.  
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Chapter 2 – General Methods 
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2.1 Introduction 
 
This thesis was funded by a British Heart Foundation Clinical Research Training Fellowship 
(FS/06/75).  
 
In this chapter I will describe each of the methods deployed for each of the studies that 
comprise the thesis. 
 
Laboratory equipment and reagents were of the highest available grades. A laboratory coat and 
latex powder-free gloves were worn during all procedures. The handling of hazardous reagents 
was in accordance with the Control of Substances Hazardous to Health Regulations 2002. 
Laboratory glassware was cleaned in Decon 75 detergent (Decon Laboratories Ltd.), rinsed 
with distilled water and dried in a 37oC cabinet. Reagents were weighed using a calibrated 
balance. Volumes from 0.1µl to 1,000µl were dispensed using appropriate Gilson pipettes 
(Gilson Medical Instruments). Volumes from 1 ml to 25 ml were measured with sterile 
disposable pipettes (Corning) and a Gilson battery-powered pipetting aid. Distilled water 
(dH20) was used to prepare aqueous solutions unless otherwise indicated. A calibrated water 
bath was utilised for experiments requiring incubations to 37°C  
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2.2 Patient selection  
 
2.2.1 The VASCAB study  
 
2.2.1.1 Ethics 
 
Ethical approval was obtained for this study from the West of Scotland Ethics Committee.  
NHS research and development approval was secured from the NHS Greater Glasgow and 
Clyde health board and the National Waiting Times Centre health board (at the Golden Jubilee 
National Hospital, Clydebank). Written informed consent was obtained for all study 
participants in accordance with the Declaration of Helsinki. Ethics approval is detailed in 
appendix 1.  
 
2.2.1.2 Patient Recruitment 
 
The Vascular Function in Coronary Artery Bypass (VASCAB) study was coordinated from 
the British Heart Foundation Glasgow Cardiovascular Research Centre (BHF GCRC). 
Volunteers were recruited prospectively at pre-operative assessment clinics in the Western 
Infirmary, Glasgow between October 2006 and February 2008, and, thereafter from the 
Cardiothoracic Unit of the West of Scotland Regional Heart and Lung Centre (at the Golden 
Jubilee National Hospital, Clydebank). Recruits were examined in the Clinical Research 
Facility of the BHF GCRC on the afternoon prior to admission or at the time of their 
admission to hospital for surgery (routinely the evening before scheduled surgery). Only 
patients with objective evidence of left ventricular systolic dysfunction (as defined by left 
ventricular ejection fraction less than 50% calculated at pre-operative trans-thoracic 
echocardiogram or ventriculogram or a subjective assessment of impaired systolic function by 
the operator) were approached as possible candidates.  
 
Moreover, only those patients receiving an individually optimised regimen of neurohormonal 
antagonists (including ACE inhibitor or ARB and beta-blocker) were included in the study and 
asked to take their medication as normal. Patients concurrently treated with hydralazine or 
long-acting nitrates were excluded. Clinical details such as smoking history, past medical 
history of myocardial infarction or hypertension and current medication were noted.  
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Routine clinical measurements including height and weight, blood pressure and resting heart 
rate were recorded. Patients were functionally assessed in accordance with the New York 
Health Association (NYHA) functional classification (146). All study participants were 
allocated a unique VASCAB study number, which served as an individual identifier for all 
clinical data and biological samples. Clinical research files were kept in a secure location in 
the BHF GCRC.  
 
2.2.2 Gluteal biopsy patients 
 
2.2.2.1 Ethics 
 
Ethical approval was obtained for this study from the West of Scotland Ethics Committee and 
NHS research and development approval from Greater Glasgow and Clyde Health Board. 
Written informed consent was obtained for all study participants in accordance with the 
Declaration of Helsinki. Ethics approval is detailed in appendix 2.  
 
 
2.2.2.2 Patient recruitment 
 
Patients with symptomatic heart failure with reduced left ventricular systolic function 
secondary to coronary artery disease were prospectively recruited from Cardiology clinics at 
the Western Infirmary, Glasgow between 2006 and 2009. Patients were provided with written 
information regarding the gluteal biopsy procedure and contacted subsequently to confirm 
their participation in the study. Transport was provided to and from the BHF GCRC for 
participants. Only those on an individually optimised regimen of neurohormonal antagonists 
(including ACE inhibitor or ARB and beta-blocker) were included in the study. Patients on 
treatment with warfarin were excluded to exclude the risk of bleeding. Patients currently 
receiving hydralazine or long acting nitrates were also excluded. All subjects attended the 
BHF GCRC for the elective biopsy procedure. Detailed past medical and therapeutic history 
was recorded in addition to NYHA functional class and basic clinical measurements including 
height and weight, blood pressure and resting heart rate. Participants in this cohort had 
relatively mild heart failure as indicated by the proportion of those receiving mineralocorticoid 
receptor antagonists and 28% who were not receiving chronic loop diuretic therapy.  
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2.3 Organ bath studies: methods for study of effects of hydralazine on human internal 
mammary arteries and long saphenous veins 
 
2.3.1 Patients 
 
Patient recruitment was undertaken as described above. Patient characteristics and 
demographics are presented in Table 2.1.  
 
All patients were in an NYHA II functional category. Participants in this cohort had relatively 
mild heart failure as indicated by the proportion of those receiving mineralocorticoid receptor 
antagonists and 28% who were not receiving chronic loop diuretic therapy. Summary data for 
age and creatinine were not available at the time of completion of this thesis.  
 
NUMBER OF PATIENTS 40 
Sex M/F 29/11 
Mean age  62y   
Previous MI 32    (80%) 
LVEF<50% 40    (100%) 
Current smoker 8      (20%) 
Atrial fibrillation 7      (17%) 
Diabetes Mellitus 12    (30%) 
Hypertension 25    (62%) 
Mean creatinine µmol/L  105   
 
Drug therapy 
ACE inhibitor/Angiotensin-receptor antagonist 40  (100%) 
β-blocker 40  (100%) 
Anti-platelet 40  (100%) 
Mineralocorticoid receptor antagonist 2    (5%) 
HMG CoA reductase inhibitor 35  (87%) 
Calcium channel antagonist 12  (30%) 
Nicorandil  8    (20%) 
Loop diuretic 35  (62%) 
Digoxin 6    (1.5%) 
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2.3.2 Vessel preparation 
 
Distal segments of left internal mammary artery (IMA) and saphenous veins (SV) were 
harvested at the time of routine coronary artery bypass surgery in the Western Infirmary and 
Golden Jubilee National Hospital. Only those segments, which were surplus to requirement, 
were provided by the theatre staff.  In some cases no tissue was available in spite of prior 
consent by patients. The discarded distal end of the IMA (1-2cm) and segments of SV (1-4cm) 
were immediately taken from theatre to the laboratory in sterile normal saline solution for 
(NaCl 0.9%) prior to transfer into chilled Krebs-HEPES solution (10mmol) on arrival to the 
BHF GCRC.  
 
Vessels were carefully cleaned of adherent fat and connective tissue under light microscopy 
and stored under refrigeration until the following day. Our group has previously shown that 
storage under these conditions does not impair vascular responses(147).  Vessels were then cut 
into 2-3mm long rings. Rings were then suspended on wires in 10ml organ chambers filled 
with physiological salt solution [(PSS) 130 mM NaCL, 4.7 mM KCL, 14.9 mM NaHCO3, 
1.18 mM KH2PO4, 5.5mM glucose, 1.17 mM MgSO4.7H2O, 1.6mM CaCl2.H20, 0.03 mM 
CaNa2EDTA and 0.02 mM indomethacin dissolved in DMSO (pH 7.49 ± 0.1)], maintained at 
37°C and aerated with a mixture of 95% O2-5% CO2. The addition of indomethacin to the PSS 
inhibited prostanoid-mediated vasoactive effects. The rings were connected to a Grass FT03 
force transducer and changes in isometric tension recorded using a MacLab dedicated 
computer.  
 
The rings of human IMA and SV were equilibrated in the organs baths in PSS solutions before 
study protocols were initiated. After stabilisation at a resting tension for approximately 1 hour, 
the harvested vessels were activated with the receptor-independent vascular smooth muscle 
cell depolarising agent potassium chloride (KCl) (100 mmol/L). The vessels were then washed 
out repeatedly for 30min and activation with KCl (100 mmol/L) repeated. The noradrenaline 
analogue phenylephrine (PE) (3 µmol/L) was used to constrict vascular rings via α-
adrenoceptors. Carbachol (a stable analogue of acetylcholine) (1 µmol/L) was used to relax 
the rings in an endothelium-dependent manner via muscarinic receptors (resulting in 
stimulated NO release) confirming endothelial integrity. After activation, vessels were further 
washed out and allowed to rest for 30 minutes before experimental protocols began.  
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Resting tension was adjusted to 1g prior to commencement of the cumulative concentration-
response curves (CCRCs) incorporated in the study protocol. Vascular rings, which did not 
contract to either KCl or phenylephrine, were discarded. Only those vessels exhibiting a 
response to carbachol were included in endothelium-dependent protocols.  
 
2.3.3. Experimental protocols 
 
Following equilibration rings were pre-constricted with PE 3 µmol/L prior to commencement 
of CCRCs determined in the study protocols.  
 
2.3.3.1 Cumulative concentration response curves to hydralazine alone 
 
The comparative vasodilator effect of hydralazine on human IMA and SVs was studied in a 
series of CCRCs in vessels taken from 20 patients. Vessels were pre-constricted as described 
before the addition of cumulative doses of hydralazine (0.01 to 10µmol/L). Plasma 
concentrations in patients receiving hydralazine for hypertension are 0.1-1.0µmol/L in patients 
taking therapeutic doses; therefore these CCRCs encompass the therapeutic and supra-
therapeutic range (79, 148-151).  Maximum relaxation responses of arteries and veins were 
determined in this series of CCRCs.  
 
 
2.3.3.2 Interaction between hydralazine and endothelium-dependent vasodilators 
 
This series of experiments sought to determine whether hydralazine augments the vasodilator 
action of the endothelially active response to the stable analogue of acetylcholine, carbachol. 
Following the initial equalisation and confirmation of endothelium integrity by response to 
carbachol (1 µmol/L), vessels were washed out and allowed to equalise for a further 30 
minutes. In pairs, vessels were pre-incubated with either hydralazine (1 µmol/L – upper limit 
of plasma concentration from studies in patients treated with hydralazine for hypertension) or 
diluent control (PSS) for 30minutes prior to pre-constriction with PE and construction of 
CCRCs to carbachol (1nmol/L-10µmol/L).  
2.3.3.3. Interaction between hydralazine and clinically relevant nitrosovasodilators  
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This series of experiments aimed to examine the hydralazine-nitrate relationship in human 
blood vessels and the relationship between nitrosovasodilators known to have differing bio-
activation pathways(152). In pairs, vessels were pre-incubated with either hydralazine (1.0 
µmol/L – concentration determined as discussed above) or diluent control (PSS) for 30 
minutes prior to pre-constriction with PE and construction of CCRCs to the high-potency 
nitrosovasodilators glyceryl-trinitrate (GTN 0.1 nmol/L -0.3µmol/L) and sodium nitroprusside 
(SNP 1 nmol/L – 30 µmol/L) and the low potency nitrosovasodilator isosorbide dinitrate 
(ISDN 0.1 nmol/L - 0.3µmol/L). Concentration ranges were selected following review of the 
relevant literature and on the basis of previous vascular reactivity experiments undertaken 
using these agents by our group(153-156). 
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2.4 Myography studies: methods for study of effects of hydralazine on human small 
resistance arteries 
 
2.4.1 Patients 
Patient recruitment was undertaken as described above. Patient characteristics and 
demographics are presented in Table 2.2 
 
All patients were in an NYHA II functional category. Participants in this cohort had relatively 
mild heart failure as indicated by the proportion of those receiving mineralocorticoid receptor 
antagonists and 15% who were not receiving chronic loop diuretic therapy. Summary data for 
age and creatinine were not available at the time of completion of this thesis. 
 
NUMBER OF PATIENTS 20 
Sex M/F 13/7 
Mean age  64y  
Previous MI 13 (65%) 
LVEF<50% 20 (100%) 
Current smoker 5   (25%) 
Atrial fibrillation 3   (15%) 
Diabetes Mellitus 8   (40%) 
Hypertension 10 (50%) 
Mean creatinine µmol/L  125 
 
Drug therapy 
ACE inhibitor/Angiotensin-receptor antagonist 20 (100%) 
β-blocker 20 (100%) 
Anti-platelet 20 (100%) 
Mineralocorticoid receptor antagonist 7   (35%) 
HMG CoA reductase inhibitor 18 (90%) 
Calcium channel antagonist 5   (25%) 
Nicorandil  4   (20%) 
Loop diuretic 17 (85%) 
Digoxin 2   (1%) 
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2.4.2 Human small resistance arteries 
 
Human small resistance arteries (SRAs) are small arteries (with diameter less than 500 µm) 
which contribute the greatest resistance to blood flow, and, as such, most involved in 
regulating blood flow and capillary pressure(157). The importance of SRAs lies in their ability 
to regulate the distribution of blood to peripheral organs through variation of their diameter 
and hence resistance to flow. These arteries can be readily obtained from gluteal biopsies in 
humans. Wire myography is an ex vivo technique which allows SRAs with a diameter of 100-
500 µm to be studied functionally and morphologically under precise and standardised 
isometric conditions and is independent of homeostatic mechanisms such as the autonomic 
nervous system or blood flow(157-159).  This technique has been adapted to facilitate the 
study of a range of animal models (including human) and vascular beds in diverse pathological 
states including chronic heart failure(160-162).  
 
2.4.3 Gluteal biopsy procedure 
 
The technique of gluteal biopsy has been used extensively in our research group as a source of 
small resistance arteries (SRA)(163-165). I received training in the technique by Dr Neal 
Padmanabhan, Senior Lecturer at the University of Glasgow. I performed all the gluteal 
biopsies in the study under local anaesthetic using sterile surgical instruments.  10-15ml of 1% 
lignocaine was injected into the upper, outer quadrant of the buttock using an aseptic 
technique. Typically the left buttock was used unless the patient had undergone gluteal biopsy 
in a previous study or had a surgical contraindication to a left-sided procedure being 
undertaken. An elliptical incision was made with a scalpel and a 2cm x 3cm x 2cm biopsy of 
gluteal skin and subcutaneous fat was taken and immediately placed in chilled PSS. 
Haemostasis was routinely achieved by manual pressure and wound closure. Three to four 
non-absorbable (silk) sutures were then used to close the skin using an interrupted mattress 
technique and a sterile dressing placed on the skin over the sutures.  
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The biopsy site, volume of local anaesthetic used, number of sutures, serial number of surgical 
instruments and immediate complications (if any) were recorded in the clinical research file. 
Patients were encouraged to gently mobilise 1 hour following the procedure and then received 
transport home. All patients were given written instructions regarding wound care and contact 
details in event of complications. Patients returned one-week post biopsy for suture removal 
and wound inspection by a member of the BHF GCRC clinical research facility nursing staff 
for which patient transport was one again provided.  Any post-biopsy complications were 
recorded in the clinical research file.  
 
2.4.4 Vessel preparation 
 
I was trained to dissect SRAs from the gluteal biopsy specimen by Ms Angela Spiers who 
kindly performed the first 4 dissections in the study. Dissection of the gluteal biopsy specimen 
was typically performed on the day of biopsy. Using surgical grade microscopic instruments 
and with the aid of a high power microscope the specimen was dissected in a Petri dish filled 
with chilled PSS, regularly changed during the dissection process, which could take several 
hours.  SRAs were isolated from surrounding subcutaneous tissue and placed in a universal 
container with PSS and refrigerated at 4°C overnight. The routine storage of SRAs in this 
manner has been demonstrated to have no effect on their vasoactive properties(166). A single 
biopsy may yield several SRAs (average 2-4). Where possible four SRAs were utilised from 
each biopsy sample.  
 
2.4.5 The Mulvany-Halpern wire myograph 
 
Wire myography is an ex vivo technique to examine the contractile and relaxant isometric 
properties of small vessels (diameters 100-500 µm). The technique was first described by 
Mulvany and Halpern in 1977(159).  In addition to functional responses, morphological data 
including internal diameter, normalised for transmural pressure, and wall thickness can be 
calculated for the vessel under investigation(157, 159). Using this technique, SRAs are 
dissected into segments of approximately 2mm in length as a ring preparation.  
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The standard approach for the procedure is for isolated rings to be carefully mounted on two 
40-µm-diameter stainless steel wires using a no-touch technique under high-power light 
microscopy and mounted in the bath of a 4-channel myograph (Danish MyoTechnology, 
Aarhus, Denmark). This consists of a base-unit on which is mounted 4 myograph blocks in 
which the wires are attached to a force transducer and micrometer respectively. A schematic 
diagram of the myograph is shown below.  
 
 
 
Figure 2.1 The Mulvany-Halpern Myograph (not to scale) 
 
 
Each bath is kept under physiological conditions with PSS which gives a pH of 7.4 when 
gassed with a 95% O2 5% CO2 mixture and pre-heated to 37°C. These conditions are 
maintained for the duration of the experiment with an in-built heater and thermostat. The 
bathing solution can be rapidly exchanged using an internal extraction system and replaced 
with fresh PSS. The next critical stage in the experimental process is mounting of the vessels. I 
was trained and assisted in the mounting of vessels by Ms. Angela Spiers and Ms. Elisabeth 
Beattie. The mounting of vessels is undertaken using high-power light microscopy.  
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Isolated rings were cannulated with pre-cut stainless steel wires within the PSS filled Petri 
dish. The wire was then transferred and connected to left myograph head. The second wire is 
then threaded through the mounted ring taking care not to damage the endothelial surface. 
Both wires were then secured to their respective myograph heads until taut. Any excess vessel 
protruding from the jaw of the myograph was cut away to ensure this segment was not able to 
contract. Vessel length was measured using a calibrated micrometer eyepiece in the dissecting 
microscope; the eyepiece having been previous calibrated using a graticule. The length of the 
vessel was then measured to far edge of the myograph jaw (α1 ocular divisions) then measured 
to near edge of segment (α2 ocular divisions) The heads of the myograph were then adjusted 
until the wires were just touching and the micrometer reading at that point (X0) was recorded. 
These measurements were recorded onto the normalisation experiment sheet prepared for the 
purposes of this study. After mounting and measurement of each isolated ring the baths were 
returned to the base unit to begin the normalisation process.  
 
2.4.6 Normalisation 
 
After a rest period of 30 minutes, a normalisation procedure was followed for each artery to 
determine the normalised internal diameter (ID), L0, at which contraction is thought to be 
optimal. This aims to set vessels to standard initial conditions to allow physiological responses 
to be measured in a reliable fashion. Some studies have indicated that the initial passive 
condition of an artery (resting tension) may influence its subsequent response to 
pharmacological agonists and antagonists(167).  Similarly, the dissection of a vessel from its 
adherent connective tissue impacts on its intrinsic pressure-length and pressure-diameter 
relationship(168).  The original technique of normalisation was designed by Mulvany and 
Halpern in an attempt to overcome these limitations(157). The intrinsic diameter of an elastic 
tissue such as an SRA is influenced by transmural pressure (and this needs to be defined by 
the normalisation process). The active response of the vessel is determined by the degree of 
stretch it is exposed to and finally the sensitivity of the vessel to pharmacological stimulation 
is also influenced by stretch. That said, even optimal ex vivo conditions cannot replicate 
dynamic in vivo physiological responses.  
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The normalisation process determines the internal circumference a vessel would have if 
relaxed and under a transmural pressure of 100mmHg (IC100).  First described in rat 
mesenteric arteries, the size of the vessel that was optimal for contraction was the IC1 or 0.9 of 
the IC100(169). Maximum active tension development can be calculated from the passive 
internal circumference/tension relationship of each vessel. Each vessel is incrementally 
distended using the micrometer and the passive force measured (F) using the chart recorder. 
Wall tension (T) is calculated by dividing the force by twice the segment length (which had 
been measured using the micrometer eyepiece). Internal circumference could be calculated 
from the micrometer reading (X0) and the knowledge that each wire has a diameter of 40 µm. 
The equivalent increase in pressure can be determined by applying the Laplace equation, 
which relates effective internal pressure, wall tension and internal circumference. The process 
is aided with the use of a programmable hand-held calculator, which is able to calculate the 
actual values from each chart reading, given the relevant calibration factors. This process is 
repeated in a stepwise sequence at 1-minute intervals to allow for “stress relaxation”; force 
recordings are taken at the end of each interval until the effective pressure has exceeded 
100mmHg.  At this point the computer fits an exponential curve to the internal circumference-
pressure data allowing calculation of the IC100. The computer can then interpolate the 
equivalent micrometer readings necessary to set the vessel to IC1 (i.e. 0.9 of IC100). The 
micrometer is then set to this point.  
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2.4.7 Myography experimental protocols  
 
Following normalisation, vessels were washed with fresh PSS and then allowed to equilibrate 
for 1 hour.  Viability of each artery is then assessed using response to a high (123 mmol/L) 
concentration potassium solution [KPSS (PSS with KCl substituted for NaCl on an equimolar 
basis)] for a series of 5-minute intervals until reproducible maximal contractions were 
achieved and then to noradrenaline (NA) (1 µmol/L). When contraction to NA had reached a 
plateau, the vessels’ endothelium-dependent vasodilator response was assessed with the 
addition of the stable analogue of acetylcholine carbachol (3 µmol/L).  Arteries that were 
unable to contract to KPSS or NA were discarded. Those that failed to relax in response to 
carbachol were not included in endothelium-dependent protocols. The arteries were then 
incubated for a further 30 minutes in fresh PSS prior to commencing cumulative 
concentration-response curves (CCRCs) incorporated in the study protocols. Reponses to 
vasodilators were expressed as a percentage relaxation following pre-constriction with 1 
µmol/L NA. 
 
2.4.7.1. Cumulative concentration response curves to hydralazine alone 
 
This series of experiments aimed to determine the vasodilator effects of hydralazine on SRAs. 
Following normalisation and a rest period of 30 minutes CCRCs to hydralazine (1 nmol/L-10 
µmol/L) were constructed in vessels pre-constricted with 1 µmol/L NA. Plasma concentrations 
in patients receiving hydralazine for hypertension are 0.1-1.0 µmol/L in patients taking 
therapeutic doses; therefore these CCRCs encompass the therapeutic and supra-therapeutic 
range (79, 148-151).  
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2.4.7.2. Interaction between hydralazine and endothelium-dependent vasodilators 
 
This series of experiments aimed to determine if hydralazine augments the vasodilator action 
of the, endothelially active response to carbachol. Following normalisation and confirmation 
of endothelial integrity by response to carbachol, vessels were pre-incubated (for 30 min at 
37ºC) in pairs with either hydralazine (1 µmol/L – concentration determined as discussed 
above) or diluent control (PSS) prior to pre-constriction with 1 µmol/L NA and construction 
of CCRCs to carbachol (1 nmol/L – 30  µmol/L).  
 
2.4.7.3. Interaction between hydralazine and clinically relevant organic 
nitrosovasodilators 
 
This series of experiments aimed to examine the hydralazine-nitrate relationship in human 
blood vessels and the relationship between nitrosovasodilators known to have differing bio-
activation pathways(152).  
 
In pairs, vessels were pre-incubated with either hydralazine (1 µmol/L – concentration 
determined as discussed above) or diluent control (PSS) for 30minutes prior to pre-
constriction with 1 µmol/L NA and construction of CCRCs to the high-potency 
nitrosovasodilators glyceryl-trinitrate (GTN 0.1 nmol/L -0.3 µmol/L) and sodium 
nitroprusside (SNP 1 nmol/L – 30 µmol/L) and the low potency nitrosovasodilator isosorbide 
dinitrate (ISDN 1 nmol/L -0.3 µmol/L). Concentration ranges were selected following review 
of the relevant literature and on the basis of previous vascular reactivity experiments 
undertaken using these agents by our group(153-156). 
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2.5 Vascular superoxide studies: methods for study of effects of hydralazine on 
superoxide production in human internal mammary arteries and long saphenous veins.  
 
2.5.1 Patients 
 
Patient recruitment was undertaken as described in Chapter 2.2.1.2 above. Residual segments 
of saphenous vein (SV) and internal mammary artery (IMA) were obtained during elective 
CABG surgery in the patient cohort described in Chapter 2.2.1.2 above. Participant 
characteristics and demographics for the entire cohort are presented in table 2.1. All patients 
met the inclusion criteria established for the study.  
 
2.5.2 Vessel preparation 
 
In the operating theatre, the vessels were immediately transferred to sterile normal saline 
solution (NaCl 0.9%) in a universal container prior to transfer to the laboratories at the BHF 
GCRC. On arrival, the vessels were immediately transferred into chilled Krebs HEPES 
solution (10mmol/L) and refrigerated at 4°C until experimental protocols were undertaken the 
following day. The vessels were then carefully dissected from adherent connective tissue 
under light microscopy and divided into 3-4 mm segments and weighed.  
The vessels were then incubated in Krebs-Ringer HEPES (KRH) buffer (119 mM NaCl, 
20mM Na-HEPES, pH 7.4, 5mM NaHCO3, 4.7 mM KCl, 1.3 mM CaCl2, 1.2 mM 
MgSO4.7H2O, 10 mM glucose, 1mM KH2PO4) until experimental protocols were undertaken. 
 
2.5.3 Lucigenin-enhanced chemiluminescence 
 
Superoxide production was measured in vascular rings by chemiluminescence using lucigenin 
(bis-N-methylacridicium). This is an established technique used by our research group and is 
the most commonly used chemiluminescence method for the detection of vascular 
superoxide(170, 171). Chemiluminescent probes are small molecules capable of crossing the 
cell plasma membrane and detect intracellular reactive oxygen species (ROS). The interaction 
of the probe with the selected ROS results in a photon-emitting reaction, which can then be 
detected (and quantified) by a luminometer or scintillation counter. Lucigenin is relatively 
specific for the detection of superoxide. Lucigenin is first reduced to produce the lucigenin 
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cation radical. Superoxide is then capable of reducing this cation to dioxetane, which 
decomposes to produce two molecules of N-methylacridone, one of which exists in the excited 
state and emits a photon upon relaxation to the ground state (figure 2.2).  
 
Lucigenin-enhanced chemiluminescence can be used to determine basal, unstimulated 
production in intact vascular segments; this facilitates superoxide measurements, which more 
closely resemble physiological conditions. One of the major concerns with this technique is 
that lucigenin can undergo redox cycling, reacting with oxygen to artificially generate 
superoxide resulting in overestimation of superoxide production. This phenomenon is well 
recognised and can be partly overcome by using low doses of lucigenin (less than 20µM)(170, 
172).  
 
Figure 2.2 The lucigenin reaction pathway 
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2.5.4 Experimental protocols 
 
Dr Carlene Hamilton assisted with the chemiluminescence experiments. Ring segments were 
placed in KRH buffer and allowed to equilibrate at 37°C for 30 minutes. Samples were then 
added to scintillation vials containing 2ml buffer and low concentration lucigenin as described 
previously by our group(170).  Samples were analysed in a liquid scintillation counter 
(Hewlett Packard Tricarb 2100TR) in the out-of-coincidence mode with a single active 
photomultiplier tube. Readings were taken every 10 seconds for 3 minutes and absolute counts 
quantified with a xanthine/xanthine oxidase calibration curve for superoxide generation and 
standardised to wet weight of the tissue. Calibration curves were in the range of 28nM to 280 
nM xanthine and prepared by adding 20 µl xanthine oxidase (0.1 U/ml), 5µM lucigenin and 
increasing volumes of 20 µM xanthine to a scintillation vial containing 2ml KRH buffer. 
Counts were reported as nmol/mg/min.  In all experiments undertaken, superoxide production 
was measured in paired samples.  
 
2.5.4.1 Basal superoxide production 
 
To investigate the effect of hydralazine on basal superoxide production pairs of rings (SV and 
IMA) were compared and pre-treated for 30min at 37 °C with a clinically relevant range of 
concentrations of hydralazine (0.01, 0.1, 1 µmol/L) with paired untreated controls. Plasma 
concentrations in patients receiving hydralazine for hypertension are ≤1.0µmol/L in patients 
taking therapeutic doses; therefore these protocols encompass the therapeutic range (79, 148-
151). 
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2.5.4.2. Angiotensin-II enhanced superoxide production in human internal mammary 
arteries 
 
Angiotensin-II (Ang II) increases vascular superoxide production through activation of 
NAD(P)H oxidase. Ang II production is one of the hallmarks of neurohormonal activation in 
heart failure with a myriad of adverse effects on blood vessels and the heart. Berry et al have 
previously demonstrated that superoxide production in greater in human IMAs than SVs and 
that Ang II-mediated superoxide production could be attenuated by drug therapy (ATR1 
receptor antagonist losartan). In this series of experiments we sought to determine whether the 
co-incubation of vessels with hydralazine could attenuate the Ang II-mediated increase in 
superoxide production and thus partly explain its favourable effects in heart failure (a clinical 
syndrome characterised by Ang II excess). Paired rings of IMA were incubated at 37°C in the 
absence (control) and presence of hydralazine (1µmol/L – concentration determined as 
discussed above) and Ang II (1µmol/L) for 4 hours prior to quantification of superoxide 
production as described in Chapter 2.5.4 above.  
 
2.6 Data and statistical analyses 
 
For clinical data and measurements in blood vessels, continuous data are shown as mean ± 
standard error of the mean (SEM), unless otherwise indicated. For comparisons of a 
continuous variable between 2 experimental groups, paired and unpaired Student's t-tests were 
applied as appropriate and, if necessary, post hoc analysis of variation with Bonferroni 
correction to account for multiple comparisons to reduce type-1 error. In vascular response 
protocols, results are expressed as relative the maximum preconstriction to PE or NE (as a 
percentage). In the case of CCRCs generated with carbachol and organic nitrates the EC50 
(concentration of agonist required to effect a 50% response was calculated to determine the 
additional effects of pre-incubation on the vasodilator action of these agents. A P-value of less 
than 0.05 (two tailed) was considered significant. Statistical analyses and graph generation 
were performed using Minitab Version 16.1.0 (© Minitab Inc 2010) and Prism 6.0 (© 
GraphPad Software Inc 2014).  
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Chapter 3 – Comparative vasodilator effect of hydralazine in 
human internal mammary arteries long saphenous veins and 
subcutaneous resistance arteries 
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3.1  Summary 
 
Hydralazine has been in clinical use as an anti-hypertensive agent for nearly six decades. 
Notwithstanding that, its mechanism of action has been poorly understood. Most of the 
literature available on its action arises from studies on animal models(99, 100, 108). 
Hydralazine appears to reduce the contractile responses to a number of vasoconstrictors, and 
this affect appears to be greater in arteries compared with veins(102, 173). Differential effects 
on arterial and venous smooth muscle may be therapeutically relevant, particularly when 
considering use in combination with other vasodilator drugs such as organic nitrates. 
Historically in vivo studies in humans suggested a preferential effect on arterial vessels(174). 
The cardinal ex vivo studies used a post mortem preparation of human metacarpal veins and 
digital arteries and examined the effect of hydralazine pre-treatment on contractile responses 
to various potent agonists. Hydralazine significantly shifted the contractile curves to the right 
(i.e. evincing antagonised contractility), more so in arteries than in with veins. There has 
hitherto never been a comprehensive assessment of the direct vasodilator effects of 
hydralazine on large and small calibre blood vessels taken from patients with chronic heart 
failure. 
 
3.2 Aims 
 
The hypothesis was that hydralazine would have a vasodilator effect on arteries and veins 
taken from patients with LVSD and CAD and have a greater effect on arteries than veins.  
 
The aims of this study were: 
 
1. To determine the comparative vasodilator effect of hydralazine on human internal 
mammary artery (IMA) and saphenous vein (SV) using therapeutically relevant 
concentrations of hydralazine.  
 
2. To determine the vasodilator effect of hydralazine on human subcutaneous resistance 
arteries using therapeutically relevant concentrations of hydralazine.  
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3.3 Patients 
 
Organ bath studies were performed in saphenous veins (SVs) and internal mammary arteries 
(IMAs) taken from patients undergoing elective CABG. All patients were recruited as part of 
the VASCAB study as described in Chapter 2.2.1.2 above.  
 
Wire myography was performed using subcutaneous resistance arteries dissected from gluteal 
biopsies from patients in chronic heart failure secondary to coronary artery disease. Detailed 
recruitment is described in Chapter 2.2.2.2 above. 
 
Participant characteristics and demographics for the entire cohort are presented in tables 2.1 
and 2.2 above respectively.  
 
3.4 Organ bath technique 
 
Rings of IMA and SV were prepared, mounted in organ baths and underwent standard start-up 
protocols as described in Chapter 2.3.2 above. All vessels were pre-constricted with the 
noradrenaline analogue phenylephrine (3 µmol/L) after which CCRCs were constructed for 
hydralazine (0.01 to 10 µmol/L). Vasodilator responses (mean+/-SEM) are expressed as 
percentage relaxation from maximally pre-constricted values. 
 
3.4.1 Hydralazine cumulative concentration response curves in human internal 
mammary arteries and saphenous veins 
 
Maximum relaxation achieved to hydralazine was 26.2±5.81% in SVs compared to 45.35 
±4.25% in IMAs (P=0.032). There was only slightly less venous dilation than arterial at 
"therapeutic" concentrations (0.1-1µmol/L). Hydralazine no significant vasodilator action at 
"therapeutic" concentrations – this  effect was observed in both veins and arteries to a similar 
degree (Figure 3-1).  
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Figure 3.1 Cumulative concentration response curves showing vasodilatation in 
saphenous vein (SV) and internal mammary artery (IMA) rings (n=10 for each) in 
response to hydralazine 0.01 to 10 µmol/L. Results shown as mean ± SEM 
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3.5 Systemic resistance artery studies 
 
3.5.1    Gluteal biopsy procedure and artery preparation 
 
Gluteal biopsies were obtained under local anaesthesia (1% lignocaine), as previously 
described in Chapter 2.4.3 above. Resistance arteries (diameter < 500 µm, length 
approximately 2mm) were dissected and mounted in the 4-channel myograph. The bath was 
gassed and heated for the duration of the experiment. Start-up and normalisation protocols 
were undertaken as previously described in Chapter 2.4.6 above. Vessel viability was 
determined by intact contractile response to KPSS (123 mmol/L) and noradrenaline (1 
µmol/L). Endothelial integrity was determined by establishing intact vasodilator response to 
the stable acetylcholine analogue carbachol (3 µmol/L). The mean internal diameter (ID) of 
the systemic resistance arteries was 344.8 ± 62.6 (SD) µm.  
 
3.5.2  Cumulative concentration response curves in human resistance arteries 
 
CCRCs were constructed to a range of therapeutically relevant concentrations of hydralazine 
(1nmol/L - 10µmol/L) or diluent control in pairs of vessels taken from 6 gluteal biopsy 
samples. All vessels were established to be viable as per start up protocols. 8 pairs of vessels 
had intact endothelium and were used in the protocol. Hydralazine had no effect compared to 
diluent control (Figure 3-2). To confirm the integrity of vasodilator responses a terminal 
addition of carbachol (3 µmol/L) was added after completion of hydralazine CCRC. This 
confirmed intact vasodilator responses in all vessels studied (data not shown).  
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Figure 3.2 Cumulative concentration response curves to hydralazine (1 nmol/L – 10 
µmol/L) or diluent control in paired endothelium-intact subcutaneous resistance arteries 
(n=8). Results are expressed as mean percentage relaxation ± SEM.  
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3.6 Summary of chapter results 
 
This is the first ex vivo assessment of the direct vasodilator effects of hydralazine on human 
blood vessels taken from patients with chronic heart failure secondary to coronary artery 
disease. In this study hydralazine had no significant vasodilator effect on subcutaneous 
resistance arteries. This was a somewhat surprising finding given our understanding that these 
vessels contribute the greatest resistance to blood flow and thus capillary pressure(157). That 
said, in the early clinical trials proving efficacy of the hydralazine-ISDN combination, clinical 
efficacy was independent of blood pressure lowering(175). In large calibre vessels, maximal 
relaxation achieved to hydralazine was significantly greater in arteries compared to veins at 
supra-maximal drug concentration. At “therapeutic concentrations” (0.1-1 µmol/L) there was 
no significant vasodilator effect. These data suggest that the therapeutic effects of hydralazine 
may not simply be dependent on arterial vasodilatation and direct vasodilator activity and that 
the observed clinical benefits of combination therapy with isosorbide dinitrate may be partly 
explained by favourable effects elsewhere; perhaps large artery stiffness.  
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Chapter 4 – Interaction between hydralazine and 
endothelium-dependent vasodilators 
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4.1  Summary 
 
Endothelial dysfunction plays a pivotal role in the development of cardiovascular disease, 
notably heart failure(176, 177). It may be a feature of heart failure of any aetiology, but is best 
characterised in heart failure secondary to coronary artery disease, where multiple contributory 
factors such as atherosclerosis, diabetes mellitus and hypertension contribute to endothelial 
impairment(178). Endothelial dysfunction is considered to be a systemic process. It may 
involve arterial, venous and microcirculatory vascular beds(179, 180). Multiple aspects of 
endothelial function can be deregulated, including vasomotor, haemostatic, anti-oxidant and 
inflammatory pathways.  
 
There are various methods available to assess endothelial function(181). The dominant ex vivo 
approach is to measure endothelium-dependent vasodilatation.  This may be impaired either 
secondary to reduced NO bioavailability, or decreased NO production (arising as a 
consequence of a legion of inter-dependent factors such as reduced NO synthase activity, 
reduced cofactor availability and impaired cellular signalling mechanisms). The 
neurotransmitter acetylcholine is a potent endothelium-dependent vasodilator, predominantly 
acting via stimulation of NO release and cGMP activation. Vascular reactivity studies can be 
undertaken in organ bath experiments and wire myography to explore acetylcholine-mediated 
vasodilatation. Clearly one of the major limitations of ex vivo assessment of vascular function 
is the availability of vessels. Although atherosclerotic lesions do not affect veins to the same 
extent as arteries, endothelial dysfunction has been demonstrated in both veins and arteries 
taken from patients with coronary artery disease and heart failure(147, 179). Given the limited 
availability of arterial samples the use of veins is therefore considered an appropriate 
surrogate.  
 
The most (though not entirely) consistent literature suggests that hydralazine leads to 
activation of guanylate cyclase. Clearly, this action to increase cGMP, if true, could explain 
the favourable clinical benefits of its combination with oral nitrates. It would therefore be 
crucial to determine if hydralazine augments endothelium-mediated vasodilatation (and thus 
NO-cGMP activity) in endothelium-intact vessels.  
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4.2 Aims 
 
This series of experiments was aimed to determine if hydralazine augments the vasodilator 
response to the endothelially-active agent carbachol.  
 
The aims of this study were: 
 
1. To determine if hydralazine augments the vasodilator response to carbachol in human 
large calibre blood vessels. 
 
2. To determine if hydralazine augments the vasodilator response to carbachol in human 
subcutaneous resistance arteries. 
 
4.3 Patients 
 
Organ bath studies were performed in saphenous veins (SVs) from patients undergoing 
elective CABG. All patients were recruited as part of the VASCAB study as described in 
Chapter 2.2.1.2. Internal mammary arteries were studied but there were insufficient data for 
inclusion in this chapter owing to lower yield at time of surgery and damage to endothelium 
during dissection and/or mounting. Whilst atherosclerotic lesions do not affect veins to the 
same extent as arteries, endothelial dysfunction has been demonstrated in both veins and 
arteries taken from patients with coronary artery disease and heart failure(147, 179). 
 
Wire myography was performed using subcutaneous resistance arteries dissected from gluteal 
biopsies from patients in chronic heart failure secondary to coronary artery disease. Detailed 
recruitment is described in Chapter 2.2.2.2 above. 
 
Participant characteristics and demographics for the entire cohort are presented in tables 2.1 
and 2.2 respectively.  
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4.4 Organ bath technique 
 
Rings of SV were prepared, mounted in organ baths and underwent standard start-up 
protocols as described in Chapter 2.3.2. All vessels were pre-constricted with the 
noradrenaline analogue phenylephrine (3 µmol/L) following which cumulative concentration 
response curves (CCRCs) were constructed. Vasodilator responses (mean+/-SEM) are 
expressed as percentage relaxation from maximally pre-constricted values. Only SV was used 
in this series of experiments because of the availability of tissue.	  
 
4.4.1 Hydralazine cumulative concentration response curves in human long saphenous 
veins 
 
CCRCs were constructed with carbachol (a stable analogue of acetylcholine) 1 nmol/l - 10 
µmol/l in the presence or absence of hydralazine (1 µmol/L) in SVs from 6 patients. Carbachol 
produced concentration-dependent relaxation in control SVs with a maximal relaxation of 
37.55% (SEM 9.86). Maximal vasodilator action to carbachol was not significantly affected 
by pre-treatment with hydralazine, with maximal relaxation of 45.86% (SEM 7.96) (P=0.239). 
Hydralazine pre-treatment did however, lead to an apparent leftward shift in the CCRC 
suggesting augmented response to carbachol although EC50 was not significantly different 
[control EC50 0.618 µmol/L hydralazine-treated EC50 of 0.288 µmol/L (P=0.87)]. (Figure 4.1) 
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Figure 4.1 Cumulative concentration response curves to carbachol (1 nmol/L - 10 
µmol/L) in pairs of human saphenous veins (n=6) in the presence (closed symbols) or 
absence (open symbols) of hydralazine (1 µmol/L). Results are expressed as mean 
percentage relaxation ±  SEM.  
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4.5 Systemic resistance artery studies 
 
4.5.1 Gluteal biopsy procedure and artery preparation 
 
Gluteal biopsies were obtained under local anaesthesia (1% lignocaine), as previously 
described (Chapter 2.4.3). Resistance arteries (diameter < 500 µm, length approximately 
2mm) were dissected and mounted in the 4-channel myograph as previously described. The 
bath was gassed and heated for the duration of the experiment. Start-up protocols were 
performed as described in Chapter 2.4.6. Following determination of viability with KPSS 
(123 mmol/L) and NA (1 µmol/L) endothelial-integrity was confirmed by vasodilator response 
to carbachol  (3µmol/L). Those that failed to relax in response to carbachol were not included 
in the protocol. The mean internal diameter (ID) of the systemic resistance arteries was 303.1± 
61(SD) µm.  
 
4.5.2 Cumulative concentration response curves in human resistance arteries 
 
CCRCs were constructed with carbachol (1nmol/L - 30 µmol/L) in presence or absence 
(diluent control) of hydralazine (1µmol/L) in 8 pairs of arteries (8 patients). Carbachol 
produced concentration-dependent relaxation in control arteries with a maximal relaxation of 
70.38 % (SEM 7.21). Maximal vasodilator action of carbachol was numerically affected by 
pre-treatment with hydralazine with a maximal relaxation of 83.00% (SEM 4.87) vs 70.38% 
(SEM 4.87). However, with two-way ANOVA for repeated measures, treatment interactions 
were not statistically significant, even at maximal concentration (P=0.0806 ANOVA). 
Hydralazine pre-treatment led to an apparent leftward shift of the CCRC with differences but 
EC50 were not statistically significant [control EC50 0.294 µmol/L and hydralazine-treated 
EC50 of 0.268 µmol/L (P=0.1)]. (Figure 4.2). 
 
 
 
 
 
 
 
	   97	  
 
 
Figure 4.2 Cumulative concentration response curves to carbachol (1nmol/L - 30 
µmol/L) in pairs of human subcutaneous resistance arteries (n=9) in the presence (closed 
symbols) or absence (open symbols) of hydralazine (1µmol/L). Results are expressed as 
mean percentage relaxation ±  SEM. * indicates statistically significant difference 
between pairs with comparison between respective groups by ANOVA.  
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4.6 Summary of chapter results 
 
These experiments demonstrate a non-significant trend towards augmented vasodilatation with 
carbachol in the presence of hydralazine in large and small calibre blood vessels taken from 
patients with chronic heart failure. Although not reaching statistical significance, there were 
numerically different maximal responses in vessels treated with hydralazine; suggesting a 
trend of potential biological relevance. Interaction of hydralazine with endothelium-dependent 
vasodilatation may contribute to the established favourable effects of hydralazine in 
combination with ISDN in patients with chronic heart failure, particularly in those known to 
have excessive degrees of endothelial dysfunction(182). The present study was undertaken 
exclusively in patients of European Caucasian origin. This study was limited by small 
numbers of vessels examined. Larger studies are needed to determine if this effect is 
significant and in other vascular preparations. It would be valuable to examine the effects of 
hydralazine in vivo using techniques to assess endothelial function in patients with heart 
failure.  
 
 With respect to ex vivo functional investigation, endothelial dysfunction generally relates to 
impaired maximal vasodilator response and/or an impaired sensitivity to endothelium- 
dependent vasodilators such as acetylcholine (and its stable analogue carbachol), bradykinin 
and calcium ionophore, with preserved response to endothelium-independent dilators such as 
sodium nitroprusside(183, 184). We only used one endothelium-dependent agonist carbachol, 
selected on the basis of published work from our group and others(185, 186). Comparison of 
the effects of hydralazine treatment on vessels with and without endothelium would allow a 
more complete assessment of the role of eNOS in the observed vasodilator activity. The 
absence of such control protocols weakens the observations of the present data. However, 
destruction of vascular wall integrity during the process of endothelial denudation destroys 
myo-endothelial gap junction communication in VSMC(187). This injury process also 
promotes oxidative stress signalling which impairs vasodilator responses(188, 189). 
Nevertheless, inclusion of such control protocols would allow a more confident attribution of 
the observed differences to endothelial mechanisms.  
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Chapter 5 – Ex vivo interaction of hydralazine with organic 
nitrates 
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5.1  Summary 
 
In combination with hydralazine, the organic nitrate ISDN has favourable effects on morbidity 
and mortality in patients with heart failure. The efficacy of this combination had originally 
been attributed to the favourable interaction of the different haemodynamic actions exerted by 
each vasodilator on the arterial and venous vasculature (hydralazine thought by many to be a 
dominant arterio-vasodilator and nitrates venodilator)(142). Neither drug on its own has 
mortality benefits in heart failure. Most now believe the therapeutic synergy is unlikely to be 
simply explained by balanced haemodynamic effects.  
 
The organic nitrates used in clinical practice are believed to vasodilate both arteries and veins 
through the release of NO and subsequent activation of guanylate cyclase in vascular smooth 
muscle. They have beneficial effects in reducing cardiac preload and afterload. Most organic 
nitrates (including GTN and ISDN) require vascular biotransformation to exert their 
pharmacological effect.  
 
In contrast, SNP is thought to spontaneously release NO and thus act as a direct (endothelium-
independent) NO donor. This process may be catalysed by vascular enzyme-systems including 
NAD(P)H oxidase(190). Long-term nitrate therapy is limited by the rapid development of 
pharmacological tolerance, possibly secondary to increased production of vascular 
superoxide(191).  
 
Hydralazine co-treatment prolongs the vasodilator effect of nitrates in animal models and 
clinical studies, though the mechanism of this protection in humans is uncertain(104, 105). 
Paradoxically, hydralazine has been shown to attenuate the vasodilator effect of SNP (through 
inhibition of NAD(P)H oxidase) in one animal model(128). We sought to explore the direct 
interaction between hydralazine and organic nitrates in human blood vessels from patients 
with chronic heart failure.  
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5.2  Aims 
 
This series of experiments was aimed to determine if hydralazine augments the vasodilator 
response to a range of clinically relevant organic nitrates.  
 
The aims of this study were: 
 
1. To determine if hydralazine augments the vasodilator response to the high-potency 
organic nitrates GTN and SNP and the low-potency organic nitrate ISDN in human 
blood vessels. 
 
 
5.3 Patients 
 
Organ bath studies were performed in saphenous veins (SVs) taken from patients undergoing 
elective CABG. All patients were recruited as part of the VASCAB study as described in 
Chapter 2.2.1.2.  
 
Wire myography was performed using subcutaneous resistance arteries dissected from gluteal 
biopsies from patients in chronic heart failure secondary to coronary artery disease. Detailed 
recruitment is described in Chapter 2.2.2.2. 
 
Participant characteristics and demographics for the entire cohort are presented in tables 2.1 
and 2.2 respectively.  
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5.4 Organ bath studies 
 
Rings of SV were prepared, mounted in organ baths and underwent standard start-up 
protocols as described in Chapter 2.3.2. All vessels were pre-constricted with 
phenylephrine (3 µmol/L) after which cumulative concentration response curves 
(CCRCs) were constructed for the specific nitrate (in a clinically relevant range) in the 
presence or absence (diluent control) of hydralazine (1µmol/L). Vasodilator responses 
(mean+/-SEM) are expressed as percentage relaxation from maximally pre-constricted 
values. 
 
 
5.4.2 Cumulative concentration response curves with organic nitrates 
 
5.4.2.1 Glyceryl-trinitrate 
 
CCRCs were constructed with GTN (0.1 nmol/L – 0.3 µmol/L) in the presence or absence of 
hydralazine (1 µmol/L) in paired rings of SVs from 8 patients from the cohort. GTN had 
marked vasodilator effect on both pairs of vessels but there was no significant difference at 
maximal relaxation with 87.5% ± 10.3 compared with 94% ± 11.2 (P=0.411). There was no 
significant shift in the CCRC with hydralazine pre-treatment [control EC50 0.0127 µmol/L 
hydralazine-treated EC50 of 0.0143 µmol/L (P=0.993)] (Figure 5.1).  
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Figure 5.1 Cumulative concentration response curves to GTN (0.1 nmol/L-0.3 µmol/L) in 
pairs of human saphenous veins (n=8) in the presence (closed symbols) or absence (open 
symbols) of hydralazine (1 µmol/L). Results are expressed as mean percentage relaxation 
±  SEM 
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5.4.2.2 Isosorbide dinitrate  
 
CCRCs were constructed with ISDN (0.1nmol/L - 3µmol/L) in the presence or absence of 
hydralazine (1µmol/L) in paired rings of SVs from 5 patients from the cohort. Maximal 
vasodilator response was 76.8% ± 14.14 in control vessels versus 74.2% ± 15.1 in 
hydralazine-treated (p=0.7). There was also no significant shift in the CCRC with hydralazine 
pre-treatment [control EC50 2.04 nmol/L hydralazine-treated EC50 0.0165 µmol/L (p=0.1)]  
(Figure 5.2).  
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Figure 5.1 Cumulative concentration response curves to ISDN (0.1nmol/L-3µmol/L) in 
pairs of human saphenous veins (n=5) in the presence (closed symbols) or absence (open 
symbols) of hydralazine (1µmol/L). Results are expressed as mean percentage relaxation 
±  SEM 
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5.4.2.3 Sodium nitroprusside 
 
CCRCs were constructed with SNP (1.0nmol/l - 30µmol/L) in the presence or absence of 
hydralazine (1µmol/L) in paired rings of SVs from 8 patients from the cohort. Maximal 
vasodilator response was 129.23% ± 8.53 in controls versus 131.1% ± 10.4 in hydralazine-
treated (P=0.8). Hydralazine pre-treatment appeared to produce a leftward shift in the SNP 
CCRC curve although this was not statistically significant [control EC50 1.39 µmol/L 
hydralazine-treated EC50 of 0.796 µmol/L (p=0.262)] (Figure 5.3). 
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Figure 5.3 Cumulative concentration response curves to SNP (1 nmol/L - 30 µmol/L) in 
pairs of human saphenous veins (n=8) in presence (closed symbols) or absence (open 
symbols) of hydralazine (1µmol/L). Results are expressed as mean percentage relaxation 
±  SEM 
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5.5  Systemic resistance artery studies 
 
5.5.1 Vessel preparation and myography procedure 
 
Gluteal biopsies were obtained under local anaesthesia (1% lignocaine), as previously 
described (Chapter 2.4.3). Resistance arteries (diameter < 500 µm, length approximately 
2mm) were dissected and mounted in the 4-channel myograph as previously described. The 
bath was gassed and heated for the duration of the experiment.  
 
The mean internal diameter (ID) of the systemic resistance arteries was 283 + 21 µm.  
 
5.5.3 Cumulative concentration response curves with organic nitrates 
 
Start-up protocols were performed as described in Chapter 2.4.6. Following determination of 
viability with KPSS (123 mmol/L) and NA (1 µmol/L) vessels were allowed to equilibrate. 
Due to time constraints for experimentation and the limited availability of human vessels to 
work with, the protocol was limited to SNP (to which hydralazine had had an apparent effect 
to shift the CCRC leftward in the organ bath protocols). Vessels were pre-treated with 
hydralazine (1 µmol/L) or diluent control for 30 minutes prior to pre-constriction with NA 
(100 µmol/L) and construction of SNP CCRC (1 nmol/L – 30 µmol/L).  
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5.5.3.1 Sodium nitroprusside 
 
CCRCs were constructed as described in 6 pairs of vessels (control/hydralazine-treated) from 
6 patients in the cohort. Vasodilator action of SNP appeared affected by pre-treatment with 
hydralazine although at maximal relaxation this was not statistically significant: 56.7% ± 
(SEM 9.9) in control vessels versus 81% ± (SEM 4.57)  (P= 0.05). Hydralazine pre-treatment 
shifted the CCRC to the left although the EC50 was not significantly different [control EC50 
0.727 µmol/L hydralazine-treated EC50 of 1.01 µmol/L (P=0.177)]. 
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Figure 5.4 Cumulative concentration response curves to SNP (1 nmol/L-30 µmol/L) in 
pairs of human subcutaneous resistance arteries (n=6) in the presence (closed symbols) 
or absence (open symbols) of hydralazine (1µmol/L). Results are expressed as mean 
percentage relaxation ±  SEM. * indicates statistically significant difference between 
pairs at given concentration.  
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5.6 Chapter summary  
 
The ex vivo interaction between hydralazine and organic nitrates appears to be very modest in 
blood vessels taken from patients with heart failure. This would tend to suggest that the 
beneficial interaction in vivo is not simply explained by direct vasodilator activity. The effects 
of the direct NO donor SNP appeared to be modestly augmented (although not reaching 
statistical significance). There is conflict in the literature about this interaction; some groups 
suggesting that hydralazine attenuate SNP-mediated vasodilatation (and subsequent cGMP 
production) whilst others found no such effect(128, 192, 193). These disparities may be partly 
explained by the diverse animal models used. In human blood vessels from patients with heart, 
this interaction has not been previously characterised.  
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Chapter 6 – Effects of hydralazine on ex vivo basal 
superoxide production in human internal mammary arteries 
and long saphenous veins.  
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6.1 Summary 
 
Heart failure is characterised by a legion of pathophysiological processes, which are thought to 
include oxidative stress(4). The term oxidative stress refers to complex interactions between 
reactive oxygen species (ROS) and anti-oxidant systems. Levels of ROS can be measured 
directly or assessed using indirect markers. The biomarkers of ROS burden have been shown 
to be elevated in heart failure and correlate with the severity of the clinical syndrome(7). The 
principal source of ROS in vivo is superoxide (O2-). This can be directly measured in vascular 
tissue or other cellular systems using a variety of techniques(172). There is a wealth of data 
directly implicating increased O2- as a major underlying mechanism in the pathophysiology of 
cardiovascular disease(58). Strategies to reduce oxidative stress (or improve nitroso-redox 
balance) are an attractive therapeutic goal.  
 
Within the heart and blood vessels there are a number of enzymatic sources of O2-. These 
include NAD(P)H oxidase, xanthine oxidase, endothelial nitric oxide synthase (NOS3) and the 
mitochondrial electron transport system(194). Of these NADH/NAD(P)H dependent oxidases 
are understood to be some of the principal sources(195). These enzyme systems are regulated 
in vivo and ex vivo by angiotensin-II and aldosterone, and are believed to play a pivotal role in 
the development of endothelial dysfunction, a key pathophysiological abnormality in heart 
failure and other cardiovascular diseases(144, 196, 197). Studies from our group have 
demonstrated elevated O2- generation in saphenous vein and internal mammary artery from 
patients with advanced coronary artery disease (CAD) undergoing CABG compared with 
vascular tissue taken from healthy controls(198). Importantly, our group has also previously 
established that angiotensin-II increases superoxide production in human internal mammary 
artery through enhanced NAD(P)H oxidase activity(170).  
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Traditional methods for the detection of O2- in vascular tissue include lucigenin-enhanced 
chemiluminescence and fluorescence techniques involving the use of probes such as 
dihydroethidium (DHE)(172). Recent applications of these techniques have succeeded in 
demonstrating increased levels of O2- in vascular tissue from patients with advanced CAD as 
compared to individuals with no documented vascular disease(198, 199). Lucigenin-enhanced 
chemiluminescence is an established and well-validated technique used by our research group 
and is the most commonly used chemiluminescence method for the detection of vascular 
superoxide(171, 197). One of the concerns of this technique is redox cycling, where lucigenin 
itself acts as a source of O2- resulting in overestimation. This can be overcome by using low 
doses of lucigenin (less than 20µM)(170, 172).  
 
As discussed previously (Chapter 1.3.2) there is an increasing body of evidence suggesting a 
favourable effect of hydralazine on nitroso-redox balance. These data have been exclusively 
restricted to animal models. Mechanistically a number of enzyme systems and processes have 
been implicated including increased soluble guanylate cyclase expression, inhibition of 
semicarbazide-sensitive amine oxidase and NAD(P)H oxidase(122, 126). The latter enzyme 
system has also been implicated in the development of vascular nitrate tolerance and is an 
attractive theoretical target for hydralazine(106). The potential anti-oxidant effects of 
hydralazine have never before been directly characterised in human blood vessels. 
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6.2 Aims 
 
The principal hypothesis was that hydralazine would reduce basal vascular O2- production in 
internal mammary arteries (IMAs) and saphenous veins (SVs) taken from patients with 
established CAD and LVSD.  
 
The aims of this study were: 
1. To assess the effect of hydralazine on basal O2- production in IMAs and SVs 
2. To assess the relative potency of hydralazine on IMAs vs. SVs 
3. To assess any apparent dose-response to hydralazine on basal O2- production.  
 
 
6.3  Patients 
 
Vascular O2- measurements were performed in SVs and IMAs from patients undergoing 
elective CABG. All patients were recruited as part of the VASCAB study as described in 
Chapter 2.2.1.2.  
 
Participant characteristics and demographics for the entire cohort are presented in table 2.1.  
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6.4 Lucigenin-enhanced chemiluminescence 
 
6.4.1  Vessel preparation 
 
O2-production was measured in 3-4 mm rings by chemiluminescence using lucigenin. Samples 
were analysed in a liquid scintillation counter (Hewlett Packard Tricarb 2100TR) in the out-
of-coincidence mode. Readings were taken every 10 seconds for 3 minutes and absolute 
counts quantified with a xanthine / xanthine oxidase calibration curve for O2- generation and 
standardised to wet weight of the tissue. Detailed methods are described in Chapter 2.5.4.  
 
To investigate the effect of hydralazine on basal O2-production we studied IMA and SV rings 
which had been pre-treated for 30min at 37°C with a range of concentrations of hydralazine 
(0.01, 0.1, 1 µmol/L). Each ring was paired with a control ring from the same subject 
incubated with buffer. 
 
 
6.4.2  Basal superoxide production IMAs and SVs from patients with heart failure 
 
We compared basal O2- production in arteries and veins from patients with heart failure. Basal 
O2-was significantly higher in IMA (n=12) compared with SV (n=12) 1.08 ± 0.14 
nmol/mg/min vs. 0.74 ± 0.08 nmol/mg/min (P=0.006) (Figure 6.1). 
 
 
6.4.3 Basal superoxide production in hydralazine treated vessels 
 
Co-administration of vessels with hydralazine (1 µmol/L) reduced basal O2- production 
significantly in both IMAs 1.09 ± 0.14 vs. 0.77 ±0 .16 nmol/mg/min (P=0.026) (Figure 6.2) 
and SVs 0.77 ± 0.08 vs. 0.68 ± 0.08 nmol/mg/min (P=0.018)  (Figure 6.3). 
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Figure 6.1 Basal O2-production in SV and IMA rings from patients with heart failure. 
Results expressed as nmol/mg/min and are shown as mean±  SEM. Red column 
represents IMA (n=12) and blue column SV (n=12) 
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Figure 6.2 Effect of hydralazine on O2-production in human IMA. Blood vessels were 
incubated in the presence or absence of hydralazine (1 µmol/L) for 30 minutes prior to 
quantification of O2-. Results are expressed as nmol/mg/min and are shown as mean ± 
SEM. Red column represents control IMAs (n=12) and shaded column hydralazine-
treated (n=12).  
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Figure 6.3 Effect of hydralazine on O2-production in human SVs. Blood vessels were 
incubated in the presence or absence of hydralazine (1 µmol/L) for 30 minutes prior to 
quantification of O2-. Results are expressed as nmol/mg/min and are shown as mean ± 
SEM. Blue column represents control SVs (n=12) and shaded column hydralazine-
treated (n=12).  
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6.4.4. Dose-response relationship to hydralazine 
 
In a series of experiments we sought to determine if there was a dose-response relationship to 
hydralazine. Paired rings of SV were incubated with either diluent control or a range of 
concentrations of hydralazine (0.01, 0.1, 1.0 µmol/L). Hydralazine at 1.0 µmol/L reduced O2- 
significantly [0.77 ± 0.08 nmol/mg/min vs. 0.68 ± 0.08 nmol/mg/min (P = 0.018)] and at 0.1 
µmol/L [0.567 ± 0.06 nmol/mg/min vs. 0.411 ± 0.05 nmol/mg/min (P = 0.025)]. There was no 
apparent effect with the lowest dose increment of 0.01 µmol/L. These data suggest an apparent 
dose-response effect with hydralazine treatment (Figure 6.4).  
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Figure 6.4 Effect of differing concentrations of hydralazine on O2-production in human 
SVs. Paired vessels were incubated in the presence or absence of hydralazine 1.0 µmol/L 
(n=12), 0.1 µmol/L (n=7) and 0.01 µmol/L (n=6) for 30 minutes prior to quantification of 
O2-. Results are expressed as nmol/mg/min and are shown as mean ± SEM.  
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6.5 Discussion 
 
Increased levels of O2- in heart failure have been shown to be proportionate to the clinical 
severity (7). In animal models of heart failure, levels of O2- production are reduced with anti-
oxidant treatment, which is associated with cardiac protection(72, 73).  In patients with 
established CAD, oxidative stress may persist despite the use of agents that have been shown 
to reduce O2- production such as ACE inhibitors, Angiotensin-type1-receptor antagonists 
(ARBs) and HMG CoA reductase inhibitors (statins)(58, 200). There therefore exists a further 
potential therapeutic target for intervention –so-called nitric-oxide enhancing therapies.  
 
To my knowledge this is the first demonstration that hydralazine reduces basal O2-production 
in human blood vessels. This effect was seen to a similar degree in both IMA and SVs. The 
experiments conducted were not paired with SV and IMA from the same subjects.  As such, 
no conclusion can be made about the relative potency of hydralazine on IMA versus SV. Berry 
et al previously demonstrated that arteries are the dominant source of vascular O2- production 
in humans, owing presumably to the greater density of VSMC in the arterial media(170). 
Nevertheless, we have demonstrated that hydralazine significantly reduces O2- production in 
both vessel types. In SVs (which were much more readily available than IMA) there was an 
apparent dose-response relationship.  
 
It should be borne in mind that this study has a number of limitations: it is an observational 
study so although its results have demonstrated O2- levels to be elevated no information on the 
clinical consequences of this effect can be proved. Furthermore, results are only available for a 
small cohort of patients limiting further subgroup analysis. Age has been associated with 
increased levels of oxidative stress(201, 202). Gender may also have effects on levels of 
oxidative stress. This study focused only on one ROS and although O2- is felt to be the key 
ROS others may also be important. It was impractical to perform paired experiments with SVs 
and IMAs taken from the same patients in order to explore the relative potency of hydralazine 
on these vessels. This was largely because of the availability of human tissue (both vessels 
were not consistently available from individual study participants). 
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This study functionally demonstrates a reduction in vascular O2- production with hydralazine 
but does not explore this mechanistically. The main enzymatic sources of O2- production 
within the vascular wall are NAD(P)H oxidase, xanthine oxidase, and endothelial NO synthase 
(eNOS)(203-205). Compared to historical data from this study group, the magnitude of effect 
of hydralazine on vascular O2- production appears comparable to that of the xanthine oxidase 
inhibitor allopurinol (0.1mmol/L) and NADH/NAD(P)H oxidase inhibitor apocynin 
(0.1mmol/L) in blood vessels taken from patients with CAD(198).  
 
To further develop understanding of hydralazine-reduced vascular production of O2- 
experiments could be designed to directly compare the effects of hydralazine with a similar 
range of enzyme-inhibitors including those of (nitric oxide synthase (NG-nitro-L-arginine-
methyl ester). Hydralazine has also been purported to have ROS scavenging properties(206) 
which is also worthy of investigation. A number of confirmatory studies could be undertaken 
to support my findings using lucigenin chemiluminescence. Oxidative fluorescent 
microptography using hydroethidine allows localisation and semi-quantification of O2- 
production and has good specificity for SO(172). Briefly, frozen section of vessel are prepared 
and incubated with the nuclear marker 4’, 6-diamidino-2-phenylindole (DAPI; 0.5 µg/ml for 2 
min) followed by hydroethidine (2 µmol/L for 20 min). Fluorescence is then detected, and 
quantified, using a laser scanning confocal microscope. In parallel Electron Paramagnetic 
Resonance (EPR) spectroscopy would confirm data on O2- generation. EPR spectroscopy is a 
highly specific method to unambiguously detect free radicals such as the O2- anion(207). 
Vessel rings are placed in buffer containing the spin probe 1-hydroxy-3-carboxy-2,2,5,5 
tetramethylpyrrolidine (CPH 500 µM) in 24-well plates and incubated at 37°C(207). Aliquots 
of this buffer are then analysed in an EPR spectrometer fitted with a temperature controller 0, 
3, 6, 10 and 15 minutes to examine the time-course of O2- release. Experiments would be 
performed at basal conditions and after pre-incubation with superoxide-dismutases to 
guarantee specificity for O2- (208). 
 
To my knowledge this is the first study to demonstrate an apparent ability for hydralazine to 
reduce basal O2- production in human blood vessels (in both arteries and veins). This outcome 
is important and may explain a component of the therapeutic benefits of hydralazine in 
combination with isosorbide dinitrate in patients with chronic heart failure, and, in particular 
the observed ability of hydralazine to reduce nitrate tolerance.  
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Chapter 7 – Effects of hydralazine on ex vivo angiotensin-II 
stimulated superoxide production in human internal mammary 
arteries 
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7.1  Summary 
 
As described in chapter 1.1.7 and 6.1, oxidative stress plays an important role in the 
pathophysiology of heart failure, and may be a future therapeutic target. Hydralazine may 
interact with a number of vascular enzyme systems including key regulators of superoxide 
(O2-) production such as NADH/NAD(P)H-dependent oxidases. These systems may be 
regulated in vivo and ex vivo by the neurohormones angiotensin-II (Ang II) and aldosterone, 
and are believed to be pivotal in the development of endothelial dysfunction; one of the 
cardinal pathophysiological processes in heart failure(144, 196). Ang II-mediated O2- 
production appears to be driven by NAD(P)H oxidase, further endorsing the critical role of 
this enzyme system in cardiovascular disease. Ang II potently stimulates NAD(P)H oxidase 
activity in a variety of models. Infusions of Ang II up-regulate production of the subunits of 
NAD(P)H oxidase and increase O2- production in animal studies(209, 210). Ang II may also 
be an important stimulant of NAD(P)H oxidase activity in humans and additionally has been 
shown to induce LOX-1 expression, the human endothelial receptor for oxidised LDL(195, 
211). Therefore the pathophysiological effects of Ang II may be pleotropic.  
 
Our group has previously demonstrated that O2- production in blood vessels from patients 
with established coronary artery disease (CAD) is greater in internal mammary artery (IMA) 
than in saphenous (veins).  This may be due to larger vascular smooth muscle cell (VSMC) 
content (170). NAD(P)H oxidase and xanthine oxidase contributed to the production of O2- in 
these vessels. This was the first study demonstrating that Ang II could increase O2- production 
in human blood vessels, although this effect was only apparent in arteries. It is known that 
Ang II exerts its pathophysiological effects differently, in different vascular beds(212). Berry 
et al also demonstrated that Ang II-mediated O2- production could be attenuated by drug 
therapy (the angiotensin type 1 receptor (ATR1) antagonist, losartan). It is, however, 
recognised that Ang II can increase O2- production via non-ATR1 or ATR2- mediated receptor 
mechanisms in some animal models(213, 214).  Whether this effect is species dependent, or 
whether yet unexplained intracellular mechanisms exist, remains to be fully investigated. As 
discussed in chapters 1.3.2 and 1.4.3, hydralazine may interact with NAD(P)H oxidase to 
improve nitroso-redox balance and potentially improve nitrate tolerance(106, 128). Assuming 
that Ang II largely stimulates this enzyme system, it would be interesting to demonstrate the 
effect of hydralazine on Ang II-stimulated O2- production in human blood vessels 
	  126	  
7.2 Aims 
 
I sought to determine if co-incubation of human IMA vessels with hydralazine could attenuate 
the Ang II-stimulated increase in O2- production and thus partly explain its favourable effects 
in heart failure (a clinical syndrome characterised by Ang II excess).  
 
 
7.3 Patients 
 
Vascular O2- measurements were performed in internal mammary arteries (IMAs) taken from 
patients undergoing elective CABG. All patients were recruited as part of the VASCAB study 
as described in Chapter 2.2.1.2.  
 
Participant characteristics and demographics for the entire cohort are presented in table 2.1.  
 
 
7.4 Angiotensin-II stimulated superoxide production 
 
7.4.1 Vessel preparation 
 
Superoxide production was measured in 3-4 mm rings of IMA by chemiluminescence using 
lucigenin. Samples were analysed in a liquid scintillation counter (Hewlett Packard Tricarb 
2100TR) in the out of coincidence mode. Readings were taken every 10 seconds for 3 minutes 
and absolute counts quantified with a xanthine / xanthine oxidase calibration curve for O2- 
generation and standardised to wet weight of the tissue. Detailed methods are described in 
Chapter 2.5.4. Paired rings of IMA were incubated at 37°C in the absence (control) and 
presence of hydralazine (1 µmol/L) and/or Ang-II (1 µmol/L) for 4 hours prior to 
quantification of O2- production as described above.  
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7.4.2 Angiotensin-II stimulated superoxide production in IMAs 
 
Vascular O2- production was significantly greater in vessels stimulated with Ang-II (1 µmol/L) 
(1.84 ± 0.618 nmol/mg/min; n=6) compared with paired un-stimulated controls (0.98 ± 0.163 
nmol/mg/min) (P=0.045). (Figure 7.1) 	  
 
7.4.3 Angiotensin-II stimulated superoxide production in hydralazine treated IMAs 
 
Incubation with hydralazine (1 µmol/L) significantly attenuated Ang-II-stimulated increase of 
O2-. In control vessels (n=9), O2- production was 1.637 ± 0.434 nmol/mg/min vs. 0.843 ± 0.144 
nmol/mg/min in hydralazine-treated vessels (n=9) (P=0.032). (Figure 7.2) 
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Figure 7.1 Effects of Ang II on O2-production in IMAs. Blood vessels were incubated in 
presence or absence of Ang II (1 µmol/L) for 4 hours prior to quantification of O2-. 
Results are expressed as nmol/mg/min and are expressed as mean ± SEM. Blue bars 
indicate control vessels (n=6); red bars Ang II exposed (n=6).  
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Figure 7.2 Effects of co-incubation with hydralazine (1 µmol/L) on Ang II-stimulated O2-
production in IMAs. Blood vessels were incubated in presence or absence of hydralazine 
(1 µmol/L) or diluent control and Ang II (1 µmol/L) for 4 hours prior to quantification 
of O2-. Results are expressed as nmol/mg/min and are expressed as mean ± SEM. Blue 
bars indicate control vessels (n=9); red bars hydralazine-treated (n=9).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	  130	  
7.5  Discussion 
 
This is the first study to demonstrate that hydralazine can attenuate Ang II-stimulated 
increased vascular O2- production in human blood vessels. This is of clinical importance as 
Ang II is known to be one of the key component in the cascade of neurohormonal activation 
that is characteristic of heart failure, and is prognostically important (4, 7). Ang II-stimulated 
increase in vascular O2- production is thought to be pathophysiologically important: leading to 
hypertrophic effects on VSMCs contributing to increased vascular tone in animal models of 
hypertension(144, 215). Our group and others have consistently demonstrated that Ang II 
increases O2- production through stimulation of NAD(P)H oxidase in a variety of animal 
models and in the human vasculature (144, 195-197). Moreover, Berry et al confirmed that the 
principal source of O2- production in human blood vessels was mediated through stimulation 
of NAD(P)H oxidase (which is regulated in vivo and ex vivo  by Ang II)(170). They also 
demonstrated that the AT1-specific receptor antagonist losartan had no effect on basal O2- 
production (unlike hydralazine in the present study), only Ang II-stimulated production.  
 
Hydralazine is thought to be an inhibitor of NAD(P)H oxidase. This may be relevant to the 
apparent ability of hydralazine to reduce nitrate tolerance. NAD(P)H oxidase is strongly 
implicated in the development of nitrate tolerance(106, 140, 141). Whilst I have not 
mechanistically demonstrated that hydralazine inhibits NAD(P)H oxidase activity per se, its 
apparent ability to significantly block Ang II stimulated O2- production is compelling. That 
said, other potential anti-oxidant effects of hydralazine have been proposed, including its 
direct scavenging effect(206). This could - potentially - help restore the nitroso-redox balance 
even in the presence of a potent stimulator of vascular O2- production such as Ang II.  
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As already noted, this study has a number of limitations. As discussed in Chapter 6, as this is 
principally an observational study no conclusions can be drawn with regard to the direct 
clinical consequences of these findings. Whilst I have demonstrated that hydralazine can block 
Ang II-stimulated O2- production, the mechanisms underlying this remain unclear. As 
discussed above, confirmatory studies could be undertaken oxidative fluorescent 
microptography using hydroethidine (to allow localisation and semi-quantification of O2- 
production) and EPR spectroscopy to unambiguously detect and quantify production of the O2- 
anion (172, 207).  
 
In order to further elaborate whether hydralazine attenuates enzymatically generated O2- 
production (specifically NADH/NAD(P)H oxidase and xanthine oxidase) a series of 
experiments comparing hydralazine with that of the known inhibitors of these enzyme systems 
may deepen the findings of this study. Protocols deployed in such further studies could then be 
repeated in vessels pre-treated with hydralazine in order to establish if hydralazine has any 
additional effect.  
 
Whatever the underlying mechanism, I have, for the first time, demonstrated that hydralazine 
functionally inhibits Ang II mediated O2- production in human vascular tissue. This is 
clinically relevant and may partly explain the favourable effects of hydralazine in heart failure 
and its interaction with organic nitrates to reduce nitrate tolerance.  
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Chapter 8 – General discussion 
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8.1  General discussion 
 
In the era prior to the emergence of evidence-based medicine, heart failure treatment was 
largely limited to symptomatic relief with diuretics and digoxin. Emphasis was then placed on 
modulating the haemodynamic abnormalities of heart failure, with small observational studies 
highlighting a favourable effect of vasodilator drugs on left ventricular compliance and 
function(216-218). A number of orally acting agents were then investigated in patients with 
refractory symptoms(142, 219, 220).  
 
The concept that “balanced vasodilatation” with the combination of hydralazine and ISDN 
(simultaneous reduction in preload with ISDN and afterload with hydralazine) would produce 
net clinical benefits then emerged with encouraging results(221). Later randomised-controlled 
studies demonstrated a survival advantage over placebo(83). This drug combination was 
subsequently shown to be inferior to the ACE inhibitor enalapril despite observations that H-
ISDN produced greater improvements in ejection fraction and exercise tolerance(84).  
 
The A-HeFT trial was biologically and ethically contentious, both in its concept and 
subsequent race-specific licensing of the fixed dose combination of H-ISDN. The US Federal 
Drug Administration’s approval of a prospective randomised-controlled trial of H-ISDN 
exclusively in self-identified African Americans was profoundly controversial(222). On 
scientific grounds there appears to be excess in morbidity and mortality in African American 
patients with heart failure as well as lesser responses to neurohormonal antagonists (85, 223). 
Biological plausibility has been derived from observations of reduced NO activity and 
worsened endothelial dysfunction in patients(182, 224). With specific reference to the 
apparent association between race and drug response in V-HeFT I/II, these data are based on 
retrospective analyses, which were not powered to determine non-inferiority.  
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Race is a poor surrogate for genetic background and consequently drug responsiveness. The 
Genetic Risk Assessment and Heart Failure (GRAHF) sub-study of A-HeFT explored the 
influence of genetic heterogeneity ofNOS3 (the gene encoding e-NOS) on clinical response to 
H-ISDN. When analysed by genotype, H-ISDN improved outcome in patients with the Glu298 
polymorphism of NOS3 but not in those with the Asp298 variant(225). Conversely, in the 
Genetic Risk Assessment of Cardiac Events (GRACE) registry of nearly 500 patients with low 
ejection fraction heart failure, 77.8% of African Americans carried the Asp298 polymorphism 
compared to 40% of Caucasians with the Glu298 variant(226). Whilst the former was 
associated with a worse event-free survival clearly a large proportion of Caucasian patients 
may carry a therapeutically relevant polymorphism; suggesting that many Caucasian patients 
may benefit from H-ISDN. Despite the apparent lack of treatment response in Caucasian 
patients in the V-HeFT studies, there was in fact a significant improvement in LVEF and 
exercise tolerance with H-ISDN compared to enalapril in V-HeFT II, and no difference 
between hospital admissions between African American or Caucasian patients in either 
study(85). Many therefore believe that the incremental clinical benefits achieved in A-HeFT 
are transferrable to a wider heart failure population. In this thesis I have investigated the 
effects of hydralazine on blood vessels from a European Caucasian population of patients with 
heart failure. 
 
Nitroso-redox balance is central to the pathophysiology of heart failure and is a potential 
therapeutic target. Imbalance results in an excess of reactive oxygen species with consequent 
reduced S-nitrosylation of physiologically important signalling molecules. This includes the 
cardiac ryanodine receptor (RyP2), which regulates intracellular calcium concentration and 
excitation-contraction coupling(227). Impaired S-nitrosylation directly leads to reduced 
contractility. Impaired NO bioavailability is also associated with reduced guanylyl cyclase 
activation and endothelial dysfunction. The degree of endothelial dysfunction appears to be 
proportionate to the severity of the clinical syndrome. Whilst the studies are relatively small, 
they consistently demonstrate an independent association between measurable endothelial 
dysfunction and poor functional class and outcome in heart failure, independent of aetiology 
(228-230).  
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Other adverse effects of impaired nitroso-redox balance include excess formation of 
peroxynitrite, driving a myriad of deleterious actions including lipid peroxidation, direct DNA 
damage and induction of apoptosis(231, 232).   Any intervention that restores nitroso-redox 
balance in heart failure could conceivably translate to improved clinical outcome. 
Improvement in endothelial function has however, not always translated into clinical 
outcomes. The beneficial effects of many strategies have been demonstrated only in short-term 
trials inadequately powered to establish outcome benefit(58, 233). These agents, for example 
anti-oxidants, have a heterogeneous mechanism of action and are not endothelium-specific. 
Oxidative stress may also persists despite the use of guideline-directed optimal medical 
therapies, which have proven clinical benefits and have been shown to impact measurably on 
levels of reactive oxygen species(200). Finally, even measureable improvement in endothelial 
function may not necessarily translate to clinical outcome in the complex syndrome of heart 
failure.  
 
In this thesis I have investigated for the first time the direct vasodilator effects of hydralazine 
on blood vessels taken from patients with heart failure secondary to coronary artery disease 
and interaction with a range of organic nitrates. The body of evidence in the literature 
suggested hydralazine reduced contractile responses to a range of vasoconstrictor agonists but 
had not explored direct vasodilator activity. This was also largely restricted to animal models. 
The scarce human data available (from post mortem studies) suggested a greater effect on 
arteries than veins (thought to be proportionate to the mass of vascular smooth muscle)(102, 
234).  
 
I have demonstrated that hydralazine (at therapeutically relevant concentrations) had no 
significant ex vivo vasodilator effect on blood vessels from patients with heart failure 
secondary to CAD. At supra-therapeutic concentrations there was very modest vasodilatation, 
largely restricted to capacitance arteries and veins. I confirmed previous data demonstrating a 
greater maximal effect on arteries, although at therapeutically relevant concentrations the 
effect was similarly absent.  
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The apparent lack of effect on SRAs was surprising. Vessels were appropriately pre-
constricted using standard protocols and intrinsic prostanoid pathways were inhibited by the 
addition of indomethacin to the PSS buffer. We understand that these vessels contribute most 
to resting vascular tone and blood pressure(235). Structural alterations in the microcirculation 
are one of the most powerful predictors of cardiovascular events in at risk patients(236).  
There was, however, no apparent effect of hydralazine even at supra-therapeutic doses. This 
was of course an ex vivo model using blood vessels taken from patients receiving guideline-
directed optimal medical therapy including in all cases an ACE inhibitor or ARB. Impaired 
vasodilator responses are well documented in SRAs from patients with heart failure(162). A 
measurable additional response in vessels from patients receiving optimal drug therapy could 
perhaps be difficult to demonstrate. There is a body of evidence documenting disparate 
vascular responses of neurohormonal therapies in large and small calibre blood vessels(235). 
There is also some heterogeneity of endothelial function within the circulation and between 
large and small calibre blood vessels and also in their inherent responses to different 
vasoconstrictor agents (237-239). My data could suggest that the therapeutic effects of 
hydralazine may not simply be dependent on arterial vasodilatation and direct vasodilator 
activity and that the observed clinical benefits of combination therapy with isosorbide dinitrate 
may be partly explained by favourable effects elsewhere e.g. through restoration of the 
nitroso-redox balance.  
 
We understand that the clinical benefits of hydralazine in combination with ISDN were 
independent of blood pressure lowering effect and also recognise that hydralazine may have 
effects beyond simple vasodilatation(175). Recently hydralazine has been shown to improve 
Ca2+ cycling and contractility in isolated cardiomyocytes in an animal model of oxidative 
stress induced cardiac injury(240). This is perhaps through antagonism of post-translational 
modifications of the RyP2 receptor associated with excess ROS (241). As described earlier, 
hydralazine has been proposed to inhibit endoplasmic reticulum Ca2+ release in vascular 
smooth muscle through regulation of the IP3 receptor (a member of the same receptor family 
as RyR2)(99, 112).  There is considerable evidence that oxidative stress induces cardiac injury 
by oxidizing cellular constituents including proteins critical for excitation-contraction 
coupling(241). It is therefore conceivable that the positive effects of H-ISDN on LVEF and 
outcome in patients with heart failure could relate to enhanced contractility and not simply 
balanced haemodynamic effect.  
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The combination of H-ISDN has favourable effects beyond the systemic vasculature. 
Pulmonary hypertension is common in heart failure and influences prognosis(242). Elevated 
pulmonary vascular resistance is a product of vascular remodelling of the pulmonary 
vasculature; partially attributed to endothelial dysfunction resulting from impaired NO 
availability and increased endothelin expression(243). In low ejection fraction heart failure H-
ISDN has marked short-term effects on pulmonary vascular resistance. This has been shown to 
correspond to improvements in right ventricular function(244, 245). Right ventricular 
dysfunction is a marker of poor prognosis in low ejection fraction heart failure(246). The 
measurable positive effects of H-ISDN on right ventricular function (which may be 
independent of systemic vascular activity) could also contribute to the clinical effects.  
 
In this thesis, hydralazine treatment produced a trend towards augmented ex vivo endothelium-
dependent vasodilatation in large and small calibre vessels although this effect was not 
significant when corrected for multiple comparisons. These protocols were limited by small 
numbers of vessels and likely underpowered. Nevertheless, the results suggest a trend of 
potential biological significance. Endothelial dysfunction may be a feature of heart failure of 
any aetiology, but is best characterised in heart failure secondary to coronary artery disease, 
where co-morbidities such as atherosclerosis, diabetes mellitus and hypertension contribute 
(178). Although there is heterogeneity of endothelial function within the circulation there are 
also data supporting correlation in large and small calibre vessels in cardiovascular 
disease(247). Whilst atherosclerotic lesions do not affect veins to the same extent as arteries, 
endothelial dysfunction has been demonstrated in both veins and arteries taken from patients 
with coronary artery disease and heart failure(147, 179). My data are consistent with the 
hypothesis that the mechanism of action of hydralazine could be partially mediated through 
improved endothelium-dependent vasodilatation. This effect could conceivably contribute to 
the clinical benefits of H-ISDN, particularly in patients with excessive endothelial 
dysfunction. As previously discussed, the presence of endothelial dysfunction influences 
outcome in heart failure. Strategies that may positively affect endothelial function could be 
therapeutically important. This thesis was undertaken exclusively in with heart failure 
secondary to coronary artery disease. Larger studies are needed to determine if this effect is 
significant and using  other vascular preparations and in vivo techniques to assess endothelial 
function in patients with heart failure of varying aetiology.  
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I sought to investigate the direct interaction between hydralazine and organic nitrates in 
vascular preparations. The combination of H-ISDN produces clinical results yet neither drug 
used in isolation influences prognosis and indeed long term treatment with organic nitrates 
may be deleterious. There is evidence that chronic treatment with most of the organic nitrates 
causes endothelial dysfunction(131, 248). This may correlate with worse clinical outcome, 
particularly post-MI(249).  Although nitrate tolerance is a complex phenomenon, one of the 
most compelling hypotheses is that nitrate therapy stimulates production of reactive oxygen 
species such as superoxide and peroxynitrite(250). Hydralazine has been shown to possess 
powerful peroxynitrite-quenching properties, which could explain in part its attenuation of 
experimental nitrate tolerance(145). Oxidative stress in response to chronic nitrate therapy 
may also activate a cross-talk phenomenon with vascular NAD(P)H oxidase resulting in 
further reactive oxygen species formation and peroxynitrite(251). Hydralazine has been 
purported to inhibit this enzyme system 
 
I have demonstrated only modest ex vivo vasodilator interaction in vessels treated acutely with 
hydralazine. This is consistent with the hypothesis that the therapeutic synergy is not simply 
dependent on vasodilator effect. However, we should be mindful that this was an ex vivo 
study. Organic nitrates undergo biotransformation processes that may be differently active in 
the in vivo state. GTN and PETN undergo mitochondrial activation, whist ISMN and ISDN are 
thought to undergo cytochrome P450 dependent biotransformation in the endoplasmic 
reticulum. The mechanistic interaction with hydralazine in vivo may be driven by intracellular 
accumulation and membrane localisation of the drug, which may not occur during acute 
administration. I demonstrated modest augmentation of the direct NO donor SNP in large 
calibre veins and SRAs. There is conflict in the literature about this interaction; some groups 
suggest that hydralazine attenuates SNP-mediated vasodilatation (and subsequent cGMP 
production) whilst others found no effect(128, 192, 193). These disparities may be partly 
explained by the diverse animal models used. In human blood vessels from patients with heart 
failure and coronary artery disease, this interaction has not been previously characterised.  	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There is an increasing body of evidence suggesting a favourable effect of hydralazine on 
nitroso-redox balance. Mechanistically a number of enzyme systems and processes have been 
implicated including increased soluble guanylate cyclase expression, inhibition of 
semicarbazide-sensitive amine oxidase and NAD(P)H oxidase(122, 126). Our group has 
established that angiotensin-II increases superoxide production in human internal mammary 
artery through enhanced NAD(P)H oxidase activity(170). The pathological effects of 
angiotensin-II may not be completely antagonised by conventional neurohormonal antagonists 
and as such there may be a therapeutic indication for drugs that could antagonise this enzyme.  
 
This is to our knowledge the first demonstration that hydralazine reduces basal O2- 
production in human blood vessels. No conclusion can be drawn on the relative potency of 
hydralazine on arteries or veins, as experiments were not paired. The observed effect on veins 
was however similar to that previously observed with potent enzyme-inhibitors such as 
allopurinol. I have however, demonstrated that hydralazine significantly reduces O2- 
production in both vessel types with an apparent dose-response relationship in SVs. This may 
explain part of the therapeutic benefits of H-ISDN in patients with chronic heart failure. As 
discussed previously this study has a number of limitations owing the small cohort of patients 
studied, the single reactive oxygen species under investigation and the semi-quantitative assay 
used. As an observational study, no conclusions can be firmly drawn between reduced 
superoxide production and clinical outcome; it is however, hypothesis generating. This study 
functionally demonstrates a reduction in vascular O2- production with hydralazine but does not 
explore this mechanistically.  
 
This is the first study to demonstrate that hydralazine can functionally attenuate Ang II-
stimulated O2- production in human blood vessels. This is clinically and functionally important 
as Ang II is central to the cascade of neurohormonal activation in heart failure, and is 
prognostically important (4, 7). Ang II increases O2- production through stimulation of 
NAD(P)H oxidase which is the dominant source of O2- in the vasculature(144, 195-197). The 
apparent ability of hydralazine to block Ang II stimulated O2- production is therapeutically 
interesting. As discussed above, other potential anti-oxidant effects of hydralazine should be 
considered, including a direct scavenging effect(206). Hydralazine could potentially help 
restore the nitroso-redox balance even in the presence of Ang II and other potent agonists of 
ROS.  
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The in vivo effects of hydralazine and nitroso-redox balance remain uncertain.  Superoxide 
production from blood can be stimulated by ADP-induced platelet aggregation and measured 
by semi-quantitative techniques such as lucigenin chemiluminescence(252). In a small 
controlled crossover trial of 14 patients with chronic heart failure (receiving at least one 
neurohormonal antagonist), short-term (2 week) administration of 25mg BD of hydralazine 
failed to impact positively on superoxide generation(253). This was in contrast to ex vivo 
studies from the same group. Interestingly this study was undertaken in European Caucasians. 
The dosage and duration of hydralazine therapy was significantly less than that proven in 
clinical trials (50mg/day vs. 140mg/day) and whilst sufficient to produce a haemodynamic 
response may not have impacted on platelet superoxide production.  
 
Besides quantitative difference in ROS production between vascular tissues and blood, there is 
undoubtedly also different utilisation of various ROS (such as superoxide and hydrogen 
peroxide) both in physiological cell signalling and in pathophysiological states(254, 255). 
There are also several features of NAD(P)H oxidase enzymes expressed in blood vessels that 
distinguish them from those in blood cells. Superoxide production from the phagocyte is 
considerably lower than that of vascular tissue, which displays a largely constitutive activity 
that is further increased by agonists such as Ang-II(256). Without a doubt the major source of 
ROS in the cardiovascular system (and as such, potential pathological effectors) are the 
NAD(P)H oxidases. In the present study I have consistently demonstrated a favourable effect 
of hydralazine in human vascular tissue taken from patients with chronic heart failure, albeit in 
an ex vivo preparation. The potential positive effects of hydralazine on nitroso-redox balance 
(and nitrate tolerance) merit future investigation in appropriately designed in vivo studies.  
 
In conclusion, the findings presented in this thesis provide insight into the mechanism of 
action of hydralazine in blood vessels from patients with heart failure. In terms of clinical 
perspective there appears to be direct correlation between the development of optimal medical 
therapy, as directed by randomised controlled clinical trials, and improved outcomes in 
patients with low ejection fraction heart failure. Despite these tangible benefits, a gap exists 
between guideline recommendations and real world prescribing of evidence-based therapies, 
notably H-ISDN. 
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8.5 Limitations of this work and future directions 
 
The major weaknesses of this thesis are evident: the number of patients recruited for this study 
was relatively small as were the number of vessels utilised in individual experiments. Whilst 
the numbers of paired samples in each study protocol were small, these reflect similar studies, 
which have yielded scientifically meaningful results(163, 257, 258). All similar experimental 
protocols are limited by both the availability and responsiveness of vascular tissue. Healthy 
controls were not included in our experimental protocols. Our group have previously 
demonstrated impaired vasodilator responses in blood vessels taken from patients with heart 
failure when compared with healthy controls(259). We have also recently demonstrated that 
superoxide production is greater in vessels taken from subjects with CAD when compared 
with those from healthy controls(198). As such, protocols were designed to specifically 
examine the effects of hydralazine in blood vessels taken from patients with heart failure and 
CAD. Nevertheless, expanding this research to include healthy control subjects could provide 
useful insight, particularly our observed finding of no significant direct ex vivo vasodilator 
activity of hydralazine. A comparative healthy control study would be valuable to confirm and 
distinguish this intriguing result. The composition of the control group may be difficult to 
balance with that of a contemporary heart failure population.   
 
Heart failure is a heterogeneous syndrome comprised of a spectrum of phenotypes from the 
acutely decompensated de novo patient to a chronic stable state. The haemodynamic and 
neurohormonal profiles of these stages may not be accurately reflected in an ex vivo model. In 
this thesis every attempt was made to include a cohort of individuals who were representative 
of the general heart failure population (secondary to CAD) and who were receiving guideline-
directed optimal medical therapy (which at that time included an ACE inhibitor/or ARB and a 
beta-blocker).  Experimental work comprised entirely of an ex vivo model and therefore may 
not adequately reflect natural variation in the response of blood vessels to endogenous and 
exogenous vasoactive substances. With respect to ex vivo functional investigation, we only 
used one endothelium-dependent agonist carbachol, selected on the basis of published work 
from our group and others(185, 186). As discussed in Chapter 4 comparison of the effects of 
hydralazine treatment on vessels with and without endothelium would allow a more complete 
assessment of the role of eNOS in the observed vasodilator activity and a more confident 
attribution of the observed differences to endothelial mechanisms. Beyond the functional 
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observation of ex vivo interactions with the endothelium, mechanistic assessment of the effects 
of hydralazine could be more thoroughly explored through a series of experiments to 
determine the effects of hydralazine on cyclic nucleotide production – particularly cGMP – 
using enzyme immunoassay. Ex vivo techniques are clearly limited by the availability of tissue 
but the results also need to be interpreted carefully as the samples may behave differently 
compared to when in vivo.  Further in vivo studies in a range of vascular beds in the typical 
heart failure patient would be desirable to confirm or refute these findings. This could include 
dorsal hand veins studies using a modified Aellig technique to document local effects of 
hydralazine and organic nitrate interaction on dorsal hand veins or forearm venous occlusion 
plethysmography to study local arterial effects on the brachial circulation.  
 
Whilst we have consistently demonstrated a functional reduction in vascular O2- production 
with hydralazine this has yet to be elaborated mechanistically. Emphasis should be placed on 
the NAD(P)H oxidase family of enzymes which are the dominant source of O2- in the 
vasculature and are strongly implicated in the development of nitrate tolerance Confirmatory 
studies could be undertaken using oxidative fluorescent microptography using hydroethidine 
(to allow localisation and semi-quantification of O2- production) and EPR spectroscopy to 
unambiguously detect and quantify production of the O2- anion (172, 207). Finally, the impact 
of hydralazine on NAD(P)H oxidase stimulated superoxide production could be assessed by 
messenger ribonucleic acid expression of relevant NAD(P)H oxidase isoforms (particularly 
NOX4) transcripts, quantified by real-time polymerase chain reaction(179). This would 
confirm our observations with mechanistic data not only at an enzymatic, but transcriptional, 
level.  
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Chapter 9 – Supplementary Data 
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 9.1 Appendix 1: Letter of ethical approval for VASCAB study 
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